СПОСОБ ПОЛУЧЕНИЯ СОДЕРЖАЩИХ АЛЬГИНАТ ПОРИСТЫХ ФОРМОВАННЫХ ИЗДЕЛИЙ

Изобретение относится к способу изготовления содержащих альгинат пористых формованных изделий, к изделиям, полученным этим способом, и применению этих изделий. Задачей изобретения является создание относительно крупноформатных формованных изделий с высокой однородностью на основе соединений альгинатов с поливалентными ионами металла, которые обладают высокой прочностью на разрыв во влажном состоянии, способны резаться на тонкие слои обычными режущими устройствами, имеют привлекательный внешний вид, так как обладают высокой степенью белизны, могут применяться в косметических или медицинских целях в качестве косметических прокладок для кожи или медицинских повязок для ран. Кроме того, необходимо обеспечить возможность получения толстых однородных пористых слоев альгината, необходимых для изготовления простым способом, прессованием и/или высечкой, соответствующих (применяемых также перорально) косметических или медицинских аппликационных форм: формованных изделий-имплантатов, таблеток насыщения ...

ПОЛИСАХАРИДНЫЕ ВОЛОКНА ДЛЯ РАНЕВЫХ ПОВЯЗОК

Изобретение относится к волокнам из природных полимеров и касается полисахаридного волокна для биомедицинских применений, таких как лечение ран. Волокно представляет собой вытянутое волокно, содержащее альгинат и полимеры оболочек семян подорожника в качестве единственных структурных компонентов волокна. Может быть включена противомикробная соль серебра. Волокно можно получать экструзией водной смеси солюбилизированных щелочью оболочек семян подорожника и альгината натрия в ванну с раствором хлорида кальция. Изобретение обеспечивает создание биологически производимых материалов, обладающих уникальным сочетанием функциональных свойств и благоприятных для окружающей среды отличительных особенностей. 5 н. и 15 з.п. ф-лы, 5 пр.

ЭМУЛЬСИОННЫЙ КОАГУЛЯНТ

Предложен эмульсионный коагулянт, который можно использовать для коагуляции материала для герметизации прокола в шине. Эмульсионный коагулянт содержит: компонент (А), имеющий размер частиц от 35 до 100 мкм и содержащий по меньшей мере один тип, выбранный из группы, состоящей из оксида алюминия, оксида магния и оксида кремния; альгинат пропиленгликоля; и компонент (В), содержащий по меньшей мере один тип, выбранный из группы, состоящей из оксида кальция, хлорида кальция, ацетата кальция и мочевины. Причем количество компонента (В) составляет от 3 до 30 вес.% от общего количества компонента (А), альгината пропиленгликоля и компонента (В). Эмульсионный коагулянт можно использовать для быстрой коагуляции материала для герметизации прокола в шине при крайне низкой температуре окружающей среды. 6 з.п. ф-лы, 11 табл.

МЕДИЦИНСКИЕ УСТРОЙСТВА, ПОКРЫТЫЕ БЫСТРО РАСТВОРЯЮЩИМСЯ БИОСОВМЕСТИМЫМ ПОКРЫТИЕМ

Изобретение относится к медицине, конкретно к медицинскому устройству, включающему биосовместимое медицинское покрытие, приклеенное к нему, в котором покрытие включает по меньшей мере одну из несшитых растворимых в воде солей (i) альгиновой кислоты, (ii) гиалуроновой кислоты или (iii) хитозана, причем покрытие полностью растворяется по меньшей мере в одной физиологической жидкости организма человека менее чем за 3 часа. Покрытие быстро растворяется из устройства. 28 з.п. ф-лы, 2 табл.

Применение альгинатных олигомеров в качестве антикоагулянтов крови

В изобретении предложен альгинатный олигомер из 2-75 мономерных остатков, где указанные мономерные остатки не несут сульфатную группу, для применения в качестве антикоагулянта крови в клинических и неклинических применениях, включая условия in vivo, ex vivo и in vitro. Дополнительно в изобретении предложено применение такого альгинатного олигомера в получении продукта или устройства, имеющего пониженную способность вызывать коагуляцию крови, где указанный альгинатный олигомер предоставлен в или на поверхности указанного продукта или устройства, а также способ предупреждения или ингибирования коагуляции крови in vitro или ex vivo, включающий приведение в контакт композиции, содержащей плазму крови, или материала, выбранного из трансплантированной ткани, или продукта или устройства, или их части, которые при применении вступают в контакт с кровью или продуктом, полученным из крови, с которым указанная композиция контактирует или может контактировать, с альгинатным олигомером из 2-50 мономерных ...

ГЕМОСТАТИЧЕСКИЕ УСТРОЙСТВА

... 1. Гемостатическое устройство, содержащее:субстрат;гемостатический глинистый материал, размещенный, по меньшей мере, на одной стороне субстрата; ипоперечно-сшитое связующее, конфигурированное для закрепления гемостатического материала на субстрате;в котором гемостатическое устройство подвергается процессу сушки;в котором связующее обладает эффектом удержания, в основном полностью, гемостатического материала на субстрате при контакте с кровью; а такжев котором устройство конфигурировано таким образом, что при обработке кровотечения применение устройства способно обеспечить абсорбцию крови в субстрат, а также обеспечить вхождение по меньшей мере части глинистого материала в контакт с кровью для ускорения свертываемости.2. Устройство по пункту 1, причем субстрат содержит, по меньшей мере, одно из нижеперечисленного: марлевый материал, тканый материал, губку, губчатую матрицу или вспененный полимер.3. Устройство по пункту 1, причем связующее представляет собой поперечно-сшитый альгинат кальция ...

МАКРОИНКАПСУЛИРОВАННЫЕ ТЕРАПЕВТИЧЕСКИЕ КЛЕТКИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Полимерна композици и формованные издели из нее

... 1. Полимерная композиция, включающая биологически распадающийся полимер, выбранный из группы, состоящей из целлюлозы, модифицированной целлюлозы или их смесей, и материал из морских растений и/или панцирей морских животных. 2. Полимерная композиция по п.1, отличающаяся тем, что материал из морских растений выбирают из группы, включающей водоросли, морские водоросли, бурые водоросли и их смеси. 3. Полимерная композиция по п.2, отличающаяся тем, что материал из морских растений выбирают из группы, включающей бурые водоросли, зеленые водоросли, красные водоросли, синие водоросли и их смеси. 4. Полимерная композиция по любому из предшествующих пунктов, отличающаяся тем, что материал из панцирей морских животных выбирают из группы, включающей морские отложения и измельченные панцири крабов, омаров, ракообразных, мидий, а также их смеси. 5. Полимерная композиция по любому из предшествующих пунктов, отличающаяся тем, что материал из морских растений и/или панцирей морских животных используют в ...

АЛЬГИНАТНОЕ ПОКРЫТИЕ ДЛЯ ОБРАБОТКИ СЕМЯН

АБСОРБИРУЮЩИЙ МАТЕРИАЛ

... 1. Абсорбирующее изделие, содержащее в качестве абсорбирующего материала волокна нерастворимого в воде алкилсульфоната полисахарида, который замещен одним типом алкилсульфоната и волокна набухают при абсорбции жидкости.2. Изделие по п. 1, где полисахарид представляет собой целлюлозу.3. Изделие по п. 1, где алкильный фрагмент алкилсульфоната представляет собой низший алкил.4. Изделие по п. 3, где алкилсульфонатный фрагмент представляет собой этилсульфонат, 1-метилэтилсульфонат или 2-метилэтилсульфонат.5. Изделие по п. 4, где алкилсульфонатный фрагмент представляет собой этилсульфонат.6. Изделие по п. 1, где абсорбирующий материал дополнительно включает армирующее волокно, смешанное или связанное с упомянутым нерастворимым в воде алкилсульфонатом полисахарида.7. Изделие по п. 6, где армирующее волокно включает термопластичное двухкомпонентное волокно, которое термически связано с упомянутым алкилсульфонатом полисахарида.8. Изделие по п. 7, где термопластичное двухкомпонентное волокно включает ...

VERNETZTE BIOKOMPATIBLE VERKAPSELUNGSZUSAMMENSETZUNGEN UND VERFAHREN

NEUE POLYMER ZUBEREITUNGEN ENTHALTENDE PERLUORIERTE VERBINDUNGEN ZUR TECHNISCHEN HANDHABUNG VON ZELLEN UND GEWEBE BEI TRANSPLANTATIONEN, UM DEN METABOLISMUS UND DIE ÜBERLEBENSRATE DER ZELLEN ZU VERBESSERN, SOWIE VERFAHREN ZU DEREN HERSTELLUNG

Folienzusammensetzungen aus Polymerisat zur Herstellung von Kapseln

Complex and uses thereof

Hydrogel composites

Pressure sensitive adhesives

An adhesive product suitable for use on wounds which comprises a backing layer of a moisture vapour transmitting polymer film and a layer of pressure adhesive containing at least 30% by weight of acrylic adhesive and at least 30% by weight of alginate, processes for the preparation thereof and methods of treating wounds therewith are described.

ADHESIVE PRODUCTS

ADHESIVE PRODUCTS

Foodstuffs

... 1,040,770. Sausage casings. UNILEVER Ltd. Nov. 18, 1964 [Nov. 20, 1963;April 24, 1964], Nos. 45873/63 and 17051/64. Heading A2B. An edible casing for sausages and the like comprises an edible fibrous protein, for example collagen, preferably having fibres of average length 5-25 mm., and an edible polysaccharide, which polysaccharide has in its uncombined state ionic groups, especially carboxyl groups, for example salts, especially the sodium salt, of alginic or pectic acid. The casing may be prepared by mixing the protein and polysaccharide, extruding, and precipitating the polysaccharide as an insoluble derivative, for example by means of a calcium chloride solution. Prior to mixing, the protein may be treated with an organic acid, e.g. citric, tartaric, or lactic acid, to swell the fibres. alternatively the swelling may be effected by an alkaline agent, such as an alkali metal hydroxide.

Surgical needle assembly

A biodegradable composite material

Manufactoring process of a biodegradable film hydophobe and transparency and film thus obtained

PROCEDURE FOR THE PRODUCTION OF FROZEN SUDSY SWEET GOODS

POLYMER MIXTURES OF ANIONI AND KATIONI POLYSACCHARIDEN AND USE OF IT

DÜNNSCHICHTBEHANDLUNGSAPPARAT

The invention relates to a thin film treatment apparatus (8) comprising a rotor (16) having at least one cylindrical section (26), at least one wiping blade (32, 33, 34, 35, 36, 41) being arranged on said cylindrical section, said wiping blade comprising at least two teeth (42, 43, 44, 42', 43', 44'), said teeth being spaced apart from each other, thereby forming a gap, which is characterized in that the average ratio V between the length L of one tooth (41) and the length G of the gap being located adjacent to the tooth is more than 2:1, respectively.

DEVICE FOR THE PRODUCTION OF ALGINATKUGELN

AQUEOUS GEL OF HYALURONSÄURE AND DESOXYNIBONUKLEINSÄURE, USABLE FOR COSMETICS AND PROCEDURES FOR ITS PRODUCTION.

PROCEDURE FOR THE PRODUCTION OF A HYDROPHOBEN TRANSPARENT ONE AND BIOLOGICAL DEGRADABLE FILM AND SO RECEIVED FILM

PLASTICS FROM ALGAE

AGGLOMERATES OR SPHERICAL PARTICLES FROM POLYVALENTEN METAL ALGINATEN, TO THE AGGLOMERATES BOUND COMPOSITIONS FOR THE CONTROLLED RELEASE, THE HEAVYSOLUBLE MEDICINES CONTAINING, AND PROCEDURE FOR YOUR PRODUCTION

COMPOSITION FOR THE PRODUCTION OF A AT LEAST PARTIAL BIOLOGICAL DEGRADABLE FOIL AS WELL AS SUCH A FOIL

Procedure for the treatment of among other things as Hilfs-und aggregate with the production of mortar od. such usable cellulose material

Procedure for the production of coverings, in particular sausage coverings

COMPOSITE MATERIAL AND USE OF IT

ADHESIVE

An aqueous adhesive composition and a process for preparing such compositions are disclosed. The composition comprises macromolecular complex comprising (A) a first component comprising (i) a framework element and (ii) a polyphenol, and (B) second component comprising a polypeptide, oligopeptide, amino acid, or polyamine. The framework element comprises (a) a polypeptide, oligopeptide, amino acid, or polyamine, (b) a polysaccharide, oligosaccharide, or monosaccharide, or a saccharide conjugate, or (c) a lignin, a lignan or a lignin conjugate. The polyphenol comprises a tannin, a tannic acid, a flavonoid, or a poly-resorcinol. An adhesive precursor composition comprising the first component is also disclosed. 13302702_1 74 ...

ADHESIVE PRODUCTS

Compositions for regulating metabolic disorders and methods of use thereof

GELS IN THE FORM OF HIGHLY HYDRATED SELF-SUPPORTING FILM, THE PROCESS FOR THEIR PREPARATION, AND THEIR USE IN THE THERAPY OF CUTANEOUS LESIONS AND/OR PATHOLOGIES

Method for the production of a polymerized product

The invention discloses a method for the production of a polymerized product comprising the following steps: - providing a polymerization device to which a polymerization mixture and a separation medium can be applied and wherein flow of said mixture and medium can be conducted in appropriate ducts for said mixture and medium, - transporting said polymerization mixture in a duct of said polymerization device thereby allowing the polymerization reaction, - transporting said mixture in a duct of said polymerization device in a continuous flow, - interrupting said continuous flow of said mixture with said separation medium so as to obtain consecutive volumes of said mixture and volumes of said separation medium, - further transporting said consecutive volumes of said mixture and volumes of said separation medium in a duct of said polymerization device wherein said mixture further polymerizes to obtain a discontinuous polymerized product, and removing said discontinuous polymerized product ...

Highly efficacious hemostatic adhesive polymer scaffold

The invention relates to biocompatible polymer gel compositions useful in facilitating and maintaining hemostasis. The biocompatible polymeric gel composition is comprised of (a) one or more than one polyanionic polymer, (b) one or more than one polycationic polymer, and (c) a solvent. A preferred composition includes sodium alginate, chitosan, and water to produce an adhesive hemostatic device that is useful in facilitating and maintaining rapid hemostasis.

Polysaccharide gel formulation having multi-stage bioactive agent delivery

Described herein are polysaccharide gel formulations including at least one inhibitor of polysaccharide degradation and methods of making the same. The methods described herein involve the steps of providing at least one polysaccharide and incorporating at least one inhibitor of degradation into the polysaccharide.

Implantable particles and related methods

Described herein are particles comprising a first compartment, a second compartment, and a compound of Formula (I), as well as compositions and methods of making and using the same. The particles may comprise a cell capable of expressing a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.

In situ formation of polymeric material

Alginate gels

COMPOSITIONS, DEVICES AND METHODS FOR TREATING FABRY DISEASE

Described herein are RPE cells engineered to secrete a GLA protein, as well as compositions, pharmaceutical preparations, and implantable devices comprising the engineered RPE cells, and methods of making and using the same for treating Fabry disease.

PROCESS FOR THE PRODUCTION OF CHEMICALLY OR ENZYMATICALLY MODIFIED POLYSACCHARIDES, AND PRODUCTS MADE THEREBY

Process for reducing viscosity in an aqueous polysaccharide composition comprising combining the aqueous composition with a non-aqueous viscosity reducing agent. In particular, processes for reducing the viscosity in an aqueous carbohydrate gum composition. In particular, processes for reducing viscosity of an aqueous composition of polysaccharide comprising combining viscosity reducing agent with the polysaccharide composition in an amount effective to form a two phase system. Products produced according to the aforementioned processes are also described. Aqueous compositions including polysaccharide and non-aqueous viscosity reducing agent, and wherein the water content of the composition is at least about 40 wt.%. Aqueous compositions including polysaccharide and non-aqueous viscosity reducing agent and wherein the viscosity of the composition is reduced by at least 10%. Processes for resolubilizing solid oxidized carbohydrate gum comprising combining aqueous solvent with the oxidized ...

IN SITU GELIFYING POWDER

The object of the present invention is a composition in powder form comprising the following polysaccharides alginic acid or sodium alginate, - pectin, chitosan, wherein the % by weight of the polysaccharides is at least 20% with respect to the total weight of the powder. The process for preparing said powder by an atomization process and its use in the treatment of cutaneous wounds and in the sector of food preservation are additional objects of the invention. Moreover, additional objects of the invention are the composition in the form of solution or liquid suspension that represents the starting material to obtain said powder and the process for preparing said liquid composition.

IMPLANTABLE DEVICES FOR CELL THERAPY AND RELATED METHODS

Described herein are implantable devices comprising means for mitigating the foreign body response (FBR) and at least one cell-containing compartment which comprises a plurality of cells (e.g., live cells) encapsulated in a polymer composition comprising a cell-binding substance (CBS), as well as compositions and methods of making and using the same. The cells are capable of expressing a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.

METHODS AND COMPOSITIONS FOR MAINTAINING THE CONFORMATION AND STRUCTURAL INTEGRITY OF BIOMOLECULES

A composition includes a target pharmaceutical or biological agent, a solution containing the target pharmaceutical or biological agent, and substrate that is soluble in the solution. The substrate is capable of being solidified via a solidification process and the solidification process causes the substrate to become physically or chemically cross-linked, vitrified, or crystallized. As a result of the solidification process, particles are formed. The target pharmaceutical or biological agent within the solution retains proper conformation to ultimately produce a desired effect.

HIGHLY EFFICACIOUS HEMOSTATIC ADHESIVE POLYMER SCAFFOLD

The invention relates to biocompatible polymer gel compositions useful in facilitating and maintaining hemostasis. The biocompatible polymeric gel composition is comprised of (a) one or more than one polyanionic polymer, (b) one or more than one polycationic polymer, and (c) a solvent. A preferred composition includes sodium alginate, chitosan, and water to produce an adhesive hemostatic device that is useful in facilitating and maintaining rapid hemostasis.

COMPOSITION AND MEDICAL DEVICE COMPRISING ACETYLSALICYLIC ACID FOR THE TREATMENT OF HUMAN PAPILLOMA VIRUS SKIN INFECTIONS

A medical device for the treatment of papilloma virus (HPV) skin infections is the object of this invention, in particular for the treatment of warts and related pathologies. In particular, this invention relates to acetylsalicylic acid for use in the topical treatment,of HPV skin infections in particular benign infections and more in particular warts. Acetylsalicylic acid may be administered by plaster or patch, both in a solid state, such as a tablet, powder or granulate, and by a hydrophilic or hydrophobic gel.

AZETIDINIUM-FUNCTIONAL POLYSACCHARIDES AND USES THEREOF

The present invention relates to polysaccharides that have been modified by-providing azetidinium functionality thereto. Such functionality can be provided by crosslinking a polysaccharide with a resin having azetidinium functional groups. In one or more aspects, the polysaccharide can comprise one or more of starch, guar gum, alginate or derivatives thereof. Polysaccharides having azetidinium functionality according to the present invention are suitable for multiple uses. Such uses include, but are not limited to, removal of one or more solid materials from a liquid, benef iciation of an ore,- removal of metallic ions from a liquid; providing oil from bitumen; and removal of mercury from synthetic gypsum. Other uses of the functionalized polysaccharides of the present invention include hydroseeding, dust control and corosion control.

METHOD FOR PRODUCING SOLID MATERIALS ON THE BASIS OF SYNTHETIC POLYMERS AND/OR BIOPOLYMERS AND USE THEREOF

The invention relates to a method for producing solid materials on the basis of synthetic polymers and biopolymers (A) by: (1) the solubilisation of (A) or of (A) and an additive (B) in a non-aqueous chaotropic liquid (C), (2) contacting of the solution or dispersion obtained (AC) or (ABC) with a liquid (D1), which is miscible with (C), in which however (A) is insoluble, to produce a phase (E) containing (A), (C) and (D1) and optionally (B) and a liquid phase (F) containing (C) and (D1), (3) optional separation of (E) from (F), (4) removal of (C) from (E) with the aid of (D1), to produce a gel (G) on the basis of (A), (5) impregnation of (G) with a liquid (D2) which is miscible with (C) and (D1) and in which at least (A) is insoluble and has a higher volatility than (D1), and (6) removal of (D1) and (D2) from (G) by evaporation. The invention also relates to the use of said materials.

HEMOSTATIC DEVICES

Hemostatic devices for promoting blood clotting can include a substrate (e.g., gauze, textile, sponge, sponge matrix, one or more fibers, etc.), a hemostatic material disposed thereon such as kaolin clay, and a binder material such as crosslinked calcium alginate with a high guluronate monomer molar percentage disposed on the substrate to substantially retain the hemostatic material material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood to accelerate clotting. Moreover, when exposed to blood, the binder has low solubility and retains a majority of the clay material on the gauze. A bandage that can be applied to a bleeding wound to promote blood clotting includes a flexible substrate and a gauze substrate mounted thereon.

CELLULOSE COMPOSITE

Disclosed is a cellulose composite which comprises cellulose and a hydrophilic gum, the cellulose composite giving a 1-mass% aqueous dispersion thereof which has a storage modulus (G') of 0.06 Pa or more when the pH thereof is 4.

FORM-IN-PLACE POLYSACCHARIDE GELS

EXTERNAL INCONTINENCE DEVICE AND VAPOR-ABSORPTIVE ADHESIVE COMPOSITIONS

An external incontinence device which reduces or eliminates maceration, skin irritation, microbial skin infiltration and infection, and urinary tract infection associated with conventional urinary catheters and incontinence devices is provided. Devices of the invention comprise, in a plurality of configurations, a housing having an outlet conduit, and several alternative means for attaching the housing to a para-meatal genital surface, including a barrier disc comprising various adhesive and medically active substances which form an occlusive adhesive seal with the para-meatal surface. Adhesive leaves made of fluid-absorptive or fluidpermeable materials are provided to adhere the device to skin while permitting removal of moisture from the underlying skin surface, thus eliminating maceration. Vapor permeable adhesives on the interior surface of the attachment elements, and a microbial-barrier layer provided on inner surfaces of the several configurations of housings are also provided. Antimicrobial ...

ABSORBENT PHYCOCOLLOIDS AND A METHOD FOR THEIR MANUFACTURE

Described is a method for preparing a water-swellable, substantially water-insoluble material. The method involves forming a first solution containing a water-soluble phycocolloid. The first solution is then added to a second solution containing an ion capable of rendering the water-soluble phycocolloid substantially water insoluble. The phycocolloid material is then removed from the second solution and subjected to a solvent exchange to remove water present in the phycocolloid material. Hollow particles can be formed by including a gelation-retarding agent in the first solution. Also described is a water-swellable, substantially water-insoluble particle defining an interior void. The particle comprises an outer shell formed from a water-insoluble phycocolloid. The outer shell defines an interior void which contains a phycocolloid.

POROUS PARTICLE AGGREGATE AND METHOD THEREFOR

A porous aggregate having a high intraaggregate volume for releasable containment of functional substances is described. The porous aggregates comprise discrete particles, preferably starch granules, bound together at least at their points of contact in the aggregates. The surfaces of the discrete particles cooperate to define an intraaggregate reticulate volume. The porous aggregate composition of this invention finds use as a high capacity carrier of functional substances for a wide variety of applications, in which the functional substance is released from the aggregate composition under the influence of mechanical compression/disintegration, by degradation or dissolution of the binder and/or particulate components, or by diffusion from the porous surface.

POLYMERS CONTAINING POLYSACCHARIDES SUCH AS ALGINATES OR MODIFIED ALGINATES

Materials which contain polysaccharide chains, particularly alginate or modified alginate chains. The polysaccharide chains may be included as side chains or auxiliary chains from a backbone polymer chain, which may also be a polysaccharide. Further, the polysaccharide chains may be cross-linked between side chains, auxiliary chains and/or backbone chains. These materials and non-modified or otherwise modified alginate materials are advantageously modified by covalent bonding thereto of a biologically active molecule for cell adhesion or other cellular interaction. Processes for preparation of these alginate materials and methods for using them, particularly for cell transplantation and tissue engineering applications.

Procédé de fabrication d'un matériau cellulosique

Künstliche Hülle, insbesondere für Nahrungsmittel, und Verfahren zu deren Herstellung

НЕАДГЕЗИВНЫЕ ЭЛАСТИЧНЫЕ ЖЕЛАТИНОВЫЕ МАТРИЦЫ

Настоящее изобретение представляет собой, по существу, неадгезивную эластичную желатиновую матрицу. Данная матрица является неадгезивной в отношении ран, тканей и органов, а также эластичной до такой степени, что является гибкой. Данная матрица представляет собой лиофилизованную смесь белка(ов), полимера(ов), сшивающего(их) агента(ов) и возможно пластификатора(ов). В данном изобретении также предложены способы получения неадгезивной эластичной желатиновой матрицы.

ПОГЛОТИТЕЛЬ, ОБРАЗУЮЩИЙ ПРИ ПОГЛОЩЕНИИ ПОПЕРЕЧНЫЕ МЕЖМОЛЕКУЛЯРНЫЕ СВЯЗИ, И СОДЕРЖАЩЕЕ ЕГО ИЗДЕЛИЕ

Обеспечивается получение поглощающего элемента и поглощающего изделия, содержащего поглощающий элемент, которое обладает превосходной влагопоглощающей (водопоглощающей) способностью и способностью предотвращения утечки (просачивания) и имеет целью достижение уменьшения массы и толщины поглощающего изделия. Поглощающий элемент содержит полисахарид, который побуждает реакцию гелеобразования в присутствии иона многовалентного металла, и источник иона многовалентного металла, в котором ион многовалентного металла подается одновременно с растворением и набуханием полисахарида или после растворения и набухания полисахарида. Поглощающее изделие, содержащее этот поглощающий элемент, может достигать превосходной влагопоглощаемости (водопоглощаемости) и способности к предотвращению утечки и, таким образом, уменьшений массы и толщины поглощающего изделия.

НЕАДГЕЗИВНЫЕ ЭЛАСТИЧНЫЕ ЖЕЛАТИНОВЫЕ МАТРИЦЫ

Настоящее изобретение представляет собой по существу неадгезивную эластичную желатиновую матрицу. Данная матрица является неадгезивной в отношении ран, тканей и органов, а также эластичной до такой степени, что является гибкой. Данная матрица представляет собой лиофилизованную смесь белка(ов), полимера(ов), сшивающего(их) агента(ов) и возможно пластификатора(ов). В данном изобретении также предложены способы получения неадгезивной эластичной желатиновой матрицы.

NON-ADHESIVE ELASTIC GELATIN MATRICES

НЕАДГЕЗИВНЫЕ ЭЛАСТИЧНЫЕ ЖЕЛАТИНОВЫЕ МАТРИЦЫ

Настоящее изобретение представляет собой, по существу, неадгезивную эластичную желатиновую матрицу. Данная матрица является неадгезивной в отношении ран, тканей и органов, а также эластичной до такой степени, что является гибкой. Данная матрица представляет собой лиофилизованную смесь белка(ов), полимера(ов), сшивающего(их) агента(ов) и возможно пластификатора(ов). В данном изобретении также предложены способы получения неадгезивной эластичной желатиновой матрицы.

SOIL HYDROPHILIZATION AGENT AND METHODS FOR USE

High-amylose sodium carboxymethyl starch sustained release excipient and process for preparing the same

A process for obtaining a spray-dried high amylose sodium carboxymethyl starch comprising a major fraction of amorphous form and optionally a minor fraction of crystalline V form, is provided. The process comprises providing an amorphous pregelatinized high amylose sodium carboxymethyl starch (HASCA); dispersing the amorphous pregelatinized HASCA in a solution comprising water and at least one first pharmaceutically acceptable organic solvent miscible with water and suitable for spray-drying; and spray-drying the dispersion to obtain the spray-dried HASCA comprising a major fraction of amorphous form and optionally a minor fraction of crystalline V form, in the form of a powder. Also provided is a spray-dried HASCA sustained-release excipient. This excipient is useful for preparing a tablet for the sustained-release of at least one drug.

Modified guaran binder for lithium ion batteries

Absorbent material

Nano-fiber composite calcium phosphate bone scaffold and preparation method thereof

Microcrystalline cewllulose compositions

Ultra-fine microcrystalline cellulose compositions are disclosed which comprise co-attrited microcrystalline cellulose and a hydrocolloid. The compositions have a mean particle size of less than 10 microns. The compositions are prepared by subjecting a high solids mixture of microcrystalline cellulose and a hydrocolloid to high shear forces in the presence of an anti slip agent preferably an aqueoussolution of an inorganic salt. The compositions are especially useful in food, pharmaceutical and cosmetic and industrial appications.

Coating shock-proof and waterproofing also constituting a decorative painting

Composed of chelation polyethylene glycol-polycyclohexose

PATE POUR LA FABRICATION PAR MOULAGE DE PRODUITS DE FIBRES DE BOIS

L'INVENTION EST RELATIVE A UNE PATE A MOULER APTE A L'EXTRUSION, CARACTERISEE EN CE QU'ELLE COMPREND UNE SUSPENSION AQUEUSE D'UNE MATIERE COMPOSEE DE FIBRES 1 OU PARTICULES DISPERSEES, ET UNE MATIERE INTRODUITE EN 8 SUSCEPTIBLE DE LIER CHIMIQUEMENT PRATIQUEMENT TOUTE L'EAU PRESENTE DANS LA SUSPENSION. ELLE CONCERNE EGALEMENT LE PROCEDE POUR LA FABRICATION DE CETTE PATE, L'APPLICATION POUR LA FABRICATION D'OBJETS MOULES, ET LES OBJETS OBTENUS.

Process for the manufacture of plastics by means of alginates and products while resulting

MODULATE SOURCE OF LIGHT HAS LED (ELECTROLUMINESCENT DIODE)

PARTICLES FORMEES Of a COMPLEX POLYELECTROLYTE OF CHITOSANE AND an ANION POLYSACCHARIDE, PRESENTING a STABILITY AMELIOREE

PASTE FOR MANUFACTURE BY MOULDING OF WOOD FIBRE PRODUCTS

SELF-FOAMING ACIDIC COMPOSITION AND PROCESS FOR THE PREPARATION THEREOF

RESIN BINDER COMPOSITIONS METHODS OF UTILIZING THE SAME AND RE SULTING PRODUCTS

알긴산의 졸-겔 전이 제어를 이용한 세포의 유동 패터닝 방법

... 본 발명은 알긴산(alginate)의 졸-겔 전이 제어를 이용한 세포의 유동 패터닝(patterning) 방법에 관한 것으로, 구체적으로 알긴산 수화젤을 이용하여 세포 부착 억제성에서 세포 부착 친화성 표면으로 변하는 신경세포 패터닝 방법을 개발하여, 알긴산 수화젤이 없는 부분에서만 신경세포가 배양되는 것을 확인하였으며, 이 후 알긴산 수화물을 제거하였을 때, 이전에 신경돌기가 자라지 않던 부위에서 신경돌기가 자라나며 신경 네트웍을 형성하는 것을 확인함으로써, 본 발명의 패터닝 방법은 신경세포체의 위치를 제어하고 신경돌기가 자유롭게 연결된 신경 네트웍을 형성하여 체내 신경망 연구에 유용하게 이용될 수 있다.

Hemostatic devices

METHOD FOR MANUFACTURING HYDROGEL TYPE AMMONIUM DETECTION SENSOR AND HYDROGEL TYPE AMMONIUM DETECTION SENSOR MANUFACTURED THEREBY

Disclosed is a method for producing a hydrogel type ammonium detection sensor, which comprises the following steps: mixing DI water and neutral polysaccharide capable of gelation, and heating the DI water and the neutral polysaccharide to prepare a mixed solution; adding anionic polysaccharide capable of gelation by a reaction with cations to the mixed solution; adding phenol, sodium hydroxide (NaOH) and sodium nitroprusside to the mixed solution; and completing gelation of the mixed solution to prepare hydrogel. COPYRIGHT KIPO 2017 (AA) Start (BB) End (S100) Step of mixing DI water and neutral polysaccharide capable of gelation, and heating the same to prepare a mixed solution (S200) Step of adding anionic polysaccharide, capable of gelation by a reaction with cations, to the mixed solution (S300) Step of adding phenol, sodium hydroxide (NaOH) and sodium nitroprusside to the mixed solution (S400) Step of completing gelation of the mixed solution to prepare hydrogel (S500) Step of adding ...

METHOD AND APPARATUS FOR MANUFACTURING HIGH DENSITY HYDROGEL SHEET

Compositions and methods of encapsulation biocompatible crosslinked

Method for the production of a polymerized product

The invention discloses a method for the production of a polymerized product comprising the following steps: providing a polymerization device to which a polymerization mixture and a separation medium can be applied and wherein flow of said mixture and medium can be conducted in appropriate ducts for said mixture and medium, transporting said polymerization mixture in a duct of said polymerization device thereby allowing the polymerization reaction, transporting said mixture in a duct of said polymerization device in a continuous flow, interrupting said continuous flow of said mixture with said separation medium so as to obtain consecutive volumes of said mixture and volumes of said separation medium, further transporting said consecutive volumes of said mixture and volumes of said separation medium in a duct of said polymerization device wherein said mixture further polymerizes to obtain a discontinuous polymerized product, and removing said discontinuous polymerized product from said ...

HYDROGEL FUNCTIONALIZED WITH A POLYMERIZABLE MOIETY AND THEIR USES AS BIOSENSORS OR BIOREACTORS

The present invention relates to a new hydrogel functionalized with a polymerizable moiety, the polymerized hydrogels, films and gels comprising the same and their use for cells, proteins, DNA or other molecules encapsulation, including use as biosensors or bioreactors.

PROCESS FOR THE PRODUCTION OF CHEMICALLY OR ENZYMATICALLY MODIFIED POLYSACCHARIDES, AND PRODUCTS MADE THEREBY

Process for reducing viscosity in an aqueous polysaccharide composition comprising combining the aqueous composition with a non-aqueous viscosity reducing agent. In particular, processes for reducing the viscosity in an aqueous carbohydrate gum composition. In particular, processes for reducing viscosity of an aqueous composition of polysaccharide comprising combining viscosity reducing agent with the polysaccharide composition in an amount effective to form a two phase system. Products produced according to the aforementioned processes are also described. Aqueous compositions including polysaccharide and non-aqueous viscosity reducing agent, and wherein the water content of the composition is at least about 40 wt.%. Aqueous compositions including polysaccharide and non-aqueous viscosity reducing agent and wherein the viscosity of the composition is reduced by at least 10%. Processes for resolubilizing solid oxidized carbohydrate gum comprising combining aqueous solvent with the oxidized ...

ALGINATE-BASED BUILDING MATERIALS

The present disclosure describes various building materials used in the building and construction industry, and to buildings or objects constructed therefrom, and to methods of making these building materials. The building materials comprise a polymeric material, such as sodium alginate and/or calcium alginate which confers significant flame-, fire- and heat-resistance or imperviousness to the materials. Other substances can be added to the materials to improve cross-linking and/or to produce resistance to fungal degradation. The building materials which can be produced, processed, or treated using the alginate polymers of the invention include, but are not limited to, wood products; masonry products; wall, roofing, flooring and siding products; and paint products. Further, sodium alginate in the form of a gel may be used as a firebreak to effectively stop the advance of grass fires, wildfires, and forest fires.

NEW HYDROGEL COMPOSITIONS FOR USE IN BIOREACTORS

This invention provides compositions and gel support systems containing inclusions of alginate gels and bacteria encapsulated in silica gels. New gel preparations provide suitable void space for growth and maintenance of the active cells, overcoming the disadvantage of prior art silica gels. The gel compositions provide suitable conditions for survival and growth of active cells, are sufficiently stable under conditions of use in biofilters and are resistant to decomposition or biodegradation by entrapped cells. The gels do not dissolve in water. The constructs containing gel compositions of the invention can be formulated so that they can be packed into a bed. The silica portion of the gel can absorb contaminants to sufficient extent whilst exhibiting low oxygen diffusivity.

POROUS PARTICLE AGGREGATE AND METHOD THEREFOR

A porous aggregate having a high intraaggregate reticular volume for releasable containment of functional substances is described. The porous aggregates comprise discrete particles, preferably starch granules, bound together at least at their points of contact in the aggregates. The surfaces of the discrete particles cooperate to define an intraaggregate reticulate volume. The porous aggregate composition of this invention finds use as a high capacity carrier of functional substances for a wide variety of applications, in which the functional substance is released from the aggregate composition under the influence of mechanical compression/disintegration, by degradation or dissolution of the binder and/or particulate components, or by diffusion from the porous surface.

HOMOLOGOUS GULURONIC ACID ALGINATE COATING COMPOSITION FOR IN-VIVO APPLICATION AND IMPLANTATION AND METHOD OF USING SAME

Disclosed is a transplantation or implantation composition which provokes a reduced immune response comprising materiel encapsulated within a physical semi-permeable barrier. At least the outermost layer of the barrier contains alginate comprised substantially of alpha-1-guluronic acid with minor amounts beta-D-mannuronic acid. The methods of making such a composition and use of the same are also disclosed.

Novel Adhesive Materials, Manufacturing Thereof, and Applications Thereof

A novel composition-of-matter, method of manufacturing thereof, and applications thereof as an adhesive, in a wide variety of different fields, and in particular, in the health care fields of medicine, dentistry, and veterinary science, for use by health care providers, such as medical, dental, and veterinary, surgeons, in procedures for reattaching or repairing body parts or components thereof, such as tissue, of (human or animal) subjects, especially under wet conditions, for example, involving adhesion of wet surfaces. The composition is comprised of a cross-linked form of a water miscible polymer, and at least one phloroglucinol type compound selected from the group consisting of: phloroglucinol, a derivative of phloroglucinol, and a polymer synthetically prepared from phloroglucinol or a derivative of phloroglucinol. An exemplary water miscible polymer is a naturally existing, or synthetically prepared, salt form of the carbohydrate alginic acid, such as sodium alginate, or alginic ...

Cross-Linked Polymer Based Hydrogel Material Compositions, Methods and Applications

A hydrogel material composition includes: (1) an alginate (or other cross-linking polymer) material; (2) an optional -hydroxy carboxylate material; and (3) an iron cation material. The hydrogel material composition with or without the -hydroxy-carboxylate material may be used in a photolithographic imaging application or a photorelease application within the context of a photoirradiation induced reduction/oxidation reaction of an iron (III) cation material to form an iron (II) cation material.

Pullulan replacements for films and coatings

This disclosure relates generally to materials configured to replace pullulan and pullulan functionalities and their use in applications such as edible films, coatings, breath or flavor strips, tablet coatings, gel caps, tobacco products, films for cheese or spice flavor delivery, films as barriers in food products, and non food products including industrial, personal care and pharmaceutical products. In addition, the materials and methods disclosed herein are configured for use in similar products that do not incorporate pullulan but would benefit from pullulan-like properties and functionalities.

Immuno-compatible hydrogel system

An immuno-compatible hydrogel system is provided that is resistant to protein binding. The hydrogel system is prepared by contacting a hydrogel solution with a cross-linking agent to form a gel, exposing the gel to an aqueous solution comprising a first polyelectrolyte to form a polyelectrolyte-coated hydrogel, exposing the polyelectrolyte-coated hydrogel to a second polyelectrolyte to form a crosslinked matrix and exposing the matrix to conditions which eliminates, or at least reduces, protein binding sites on the matrix.

Xanthan gum and swellable particulate containing composition and uses thereof

This invention relates to a composition comprising at least about 0.2% w/w xanthan gum and at least about 6% w/w of a swellable particulate, and to uses thereof.

Biodegradable composition comprising polymers of natural origin and aliphatic-aromatic copolyesters

The present invention relates to a biodegradable composition comprising at least one polymer of natural origin and at least one aliphatic-aromatic copolyester obtained starting from mixtures comprising aliphatic diols, polyfunctional aromatic acids, and at least two aliphatic dicarboxylic acids, at least one of which is long chain. Said composition combines improved biodegradability, excellent mechanical properties, a high level of industrial processability, limited environmental impact as well as stability of physical properties under the influence of environmental factors.

Aliphatic-aromatic copolyesters and their mixtures

This invention relates to an aliphatic-aromatic copolyester characterised in that it has appreciable workability properties even when mixed with other polymers, appreciable toughness and high values for ultimate tensile strength and elastic modulus. This invention also relates to mixtures of the said copolyester with other polymers.

INTERPENETRATING NETWORKS WITH COVALENT AND IONIC CROSSLINKS

The invention features a composition comprising a self-healing interpenetrating network hydrogel comprising a first network and a second network. The first network comprises covalent crosslinks and the second network comprises ionic or physical crosslinks. For example, the first network comprises a polyacrylamide polymer and second network comprises an alginate polymer. 136.-. (canceled)37. An interpenetrating networks hydrogel comprising a first network and a second network , wherein:the first network comprises a covalently crosslinked polymer selected from the group consisting of polyacrylamide, poly(vinyl alcohol), poly(ethylene oxide) and its copolymers, polyethylene glycol (PEG), methacrylated PEG, and polyphosphazene; andthe second network comprises an ionically crosslinked polymer selected from the group consisting of alginate, chitosan, and agarose; andthe covalently crosslinked polymer has a crosslinking density that is derived from a weight ratio between a covalent crosslinking agent and a monomer of the covalently crosslinked polymer of between about 0.031 wt. % and 0.124 wt. % based on the monomer weight.38. The hydrogel of claim 37 , wherein the first network and the second network are covalently coupled.39. The hydrogel of claim 37 , wherein the first network comprises polyacrylamide or polyethylene glycol (PEG) and wherein the second network comprises alginate.40. The hydrogel of claim 37 , wherein the covalent crosslinking agent is selected from the group consisting of N claim 37 ,N-methylenebisacrylamide (MBAA) claim 37 , a methacrylate crosslinker claim 37 , N claim 37 ,N′-dicyclohexylcarbodiimide (DCC) claim 37 , 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (ECC) claim 37 , N-hydroxysuccinimide claim 37 , N-hydroxysulfosuccinimide claim 37 , glutaraldehyde claim 37 , and a transglutaminase.41. The hydrogel of claim 37 , wherein the covalently crosslinked polymer has a crosslinking density that is derived from a weight ratio between a covalent ...

METHOD OF MANUFACTURING THREE-DIMENSIONAL STRUCTURE, THREE-DIMENSIONAL STRUCTURE, AND THREE-DIMENSION FORMATION COMPOSITION

There is provided a method of manufacturing a three-dimensional structure, in which the three-dimensional structure is manufactured by laminating a layer, the method including: forming the layer using a three-dimension formation composition containing particles, a binding resin, and a solvent; applying a binding solution containing a binder to the layer; and removing the particles, which are not bound by the binder, using a removing solution after repeating the forming of the layer and the applying of the binding solution, in which, in the removing of the unbound particles, the binding resin has a water-soluble functional group whose pKa in water is less than the pH of the removing solution. 1. A method of manufacturing a three-dimensional structure , in which the three-dimensional structure is manufactured by laminating a layer , the method comprising:forming the layer using a three-dimension formation composition containing particles, a binding resin, and a solvent;applying a binding solution containing a binder to the layer; andremoving the particles, which are not bound by the binder, using a removing solution after repeating the forming of the layer and the applying of the binding solution,wherein, in the removing of the unbound particles, the binding resin has a water-soluble functional group whose pKa in water is less than the pH of the removing solution.2. The method of manufacturing a three-dimensional structure according to claim 1 ,wherein the pKa of the water-soluble functional group in water is 6 or less.3. The method of manufacturing a three-dimensional structure according to claim 1 ,wherein the water-soluble functional group is a carboxyl group or a sulfo group.4. The method of manufacturing a three-dimensional structure according to claim 1 ,wherein the binding resin having a carboxyl group as the water-soluble functional group contains one or more selected from the group consisting of a reaction product of an olefin-maleic anhydride copolymer with ...

BACTERIAL CULTURES AND METHODS FOR PRODUCTION OF ALGINATE

Bacterial cultures are provided that comprise a modified bacterium missing or deficient in two or more virulence factors. The two or more virulence factors can be selected from exotoxin A, hemolytic phospholipase C, phenazine-specific methyltransferase, alpha-1,3-rhamnosyltransferase, and 3-phosphoshikimate 1-carboxyvinyltransferase. Certain of the modified bacteria are also missing or deficient in one or more alginate acetylation enzymes including the alginate Oacetyltransferases AlgI, AlgJ, AlgF, AlgX, and/or the C5-mannuronan epimerase AlgG. Methods of producing alginate are also provided along with compositions comprising alginate produced by the modified bacteria. 1Pseudomonas aeruginosa. A bacterial culture , comprising a modified bacterium missing or deficient in two or more virulence factors , the two or more virulence factors selected from the group consisting of exotoxin A , hemolytic phospholipase C , phenazine-specific methyltransferase , alpha-1 ,3-rhamnosyltransferase , and 3-phosphoshikimate 1-carboxyvinyltransferase.2Pseudomonas aeruginosa. The bacterial culture of claim 1 , wherein the modified bacterium is missing or deficient in exotoxin A claim 1 , hemolytic phospholipase C claim 1 , phenazine-specific methyltransferase claim 1 , alpha-1 claim 1 ,3-rhamnosyltransferase claim 1 , and 3-phosphoshikimate 1-carboxyvinyltransferase.3Pseudomonas aeruginosa. The bacterial culture of claim 1 , wherein the modified bacterium includes a deletion of two or more virulence factor genes claim 1 , the virulence factor genes selected from toxA claim 1 , plcH claim 1 , phzM claim 1 , wapR claim 1 , aroA claim 1 , and combinations thereof.4Pseudomonas aeruginosa. The bacterial culture claim 1 , wherein the modified bacterium is missing or deficient in one or more alginate acetylation enzymes claim 1 , the one or more alginate acetylation enzymes selected from the group consisting of alginate O-acetyltransferase AlgI claim 1 , alginate O-acetyltransferase AlgJ ...

ALGINATES FOR CORROSION AND SCALE CONTROL

Provided herein are methods for inhibiting the formation of scale on equipment in contact with a produced fluid containing a scale-forming divalent cation. Such methods can comprise adding an activated alginate to the produced fluid in an amount effective to react with the divalent cation in the produced fluid to form an activated alginate complex; and separating the activated alginate complex from the produced fluid. Methods can further comprise recycling the activated alginate from the activated alginate complex by dissolving the activated alginate complex. The activated alginate can be prepared by thermally modifying an alginate precursor at a temperature of from 80° C. to 180° C. for a period of at least 24 hours. The activated alginate can be in the form of a solution including 0.1% to 10% by weight activated alginate, based on the total weight of the solution. The activated alginate can exhibit increased solubility in water and kinetics of complexation with the divalent cation compared to the alginate precursor. 1. A method of inhibiting formation of scale on equipment in contact with a produced fluid containing a scale-forming divalent cation , the method comprising:thermally modifying an alginate precursor under conditions effective to afford an activated alginate that dissolves in less than 60 seconds into water and glycol phases at a concentration of 1% by weight at 25° C.;adding the activated alginate to the produced fluid in an amount effective to react with the divalent cation in the produced fluid to form an activated alginate complex; andseparating the activated alginate complex from the produced fluid.2. The method of claim 1 , wherein thermally modifying the alginate precursor is performed in an open container or under inert atmosphere.3. The method of claim 1 , wherein the alginate precursor is thermally modified at a temperature of 80° C. or greater claim 1 , such as 120° C. or greater claim 1 , or 140° C. or greater.4. The method of claim 3 , ...

Process for continuous supercritical drying of aerogel particles

Processes for drying gel particles, in particular for producing aerogels, involve providing a suspension containing gel particles and a solvent, introducing the suspension into a column where carbon dioxide flows in countercurrent, and removing dried aerogel particles from the column. The suspension is introduced in the top region of the column and dried aerogel particles are removed in the lower region. Pressure and temperature in the column are set such that the mixture of carbon dioxide and solvent is virtually supercritical or is supercritical. The aerogel particles can be discharged via discharge vessels or continuous decompression. Aerogel particles can be obtained by such a process and the aerogel particles can be used for medical and pharmaceutical applications, as additive or carrier material for additives for foods, as catalyst support, for cosmetic, hygiene, washing and cleaning applications, for production of sensors, for thermal insulation, or as a core material for VIPs.

CORROSION INHIBITOR COMPOSITION AND METHODS OF INHIBITING CORROSION DURING ACID PICKLING

A corrosion inhibitor composition, which includes i) an aqueous alcohol base fluid, ii) a mixture of at least three polysaccharides selected from carboxymethyl cellulose, gum arabic, pectin, a salt of alginic acid, chitosan, dextran, hydroxyethyl cellulose, and soluble starch, with each polysaccharide that is present in the mixture being present in an amount of 0.05 to 0.5 wt. %, based on a total weight of the corrosion inhibitor composition, iii) silver nanoparticles, and iv) a pineapple leaves extract. A method of inhibiting corrosion of metal during acid cleaning/pickling whereby the metal is treated with an acidic treatment fluid containing an acid and the corrosion inhibitor composition. 1. A corrosion inhibitor composition , comprising:a base fluid comprising water and an alcohol;a mixture of at least three polysaccharides selected from the group consisting of carboxymethyl cellulose, gum arabic, pectin, a salt of alginic acid, chitosan, dextran, hydroxyethyl cellulose, and soluble starch, with each polysaccharide that is present in the mixture being present in an amount of 0.05 to 0.5 wt. %, based on a total weight of the corrosion inhibitor composition;silver nanoparticles; anda pineapple leaves extract.2. The corrosion inhibitor composition of claim 1 , wherein the alcohol is a monoalcohol.3. The corrosion inhibitor composition of claim 1 , wherein the alcohol is isopropanol.4. The corrosion inhibitor composition of claim 1 , wherein a ratio of water to the alcohol by volume is 2:1 to 1:2.5. The corrosion inhibitor composition of claim 1 , wherein three polysaccharides are present in the mixture.6. The corrosion inhibitor composition of claim 5 , wherein each of the three polysaccharides is present in an amount of 30 to 40 wt. % claim 5 , based on a total weight of the mixture.7. The corrosion inhibitor composition of claim 1 , wherein the mixture consists of carboxymethyl cellulose claim 1 , gum arabic claim 1 , and pectin.8. The corrosion inhibitor ...

NATURAL POLYMER BASED TISSUE ADHESIVE WITH HEALING PROMOTING PROPERTIES

A tissue adhesive with healing promotion properties formed from a mixture of natural polymers and an activating agent that enhances the adhesive properties of the natural polymer mixture is described. Use of an activating agent and a combination of the natural polymers is unique. The natural polymer tissue adhesive may be useful as a post-operative application for tonsillectomy or adenoidectomy surgery, as an internal tissue adhesive for surgery or wound repair or for application to a burn or skin donor site. For internal use, an optional treatment to improve resistance of the activated adhesive to body fluids is also described. The adhesive described not only functions as an adhesive but would also serve as a protective barrier when applied to surgery or skin sites. In addition, the natural polymers would promote healing due to the inherent properties of the polymers selected. 1. A tissue adhesive suitable for skin contact or internal use comprisinga. a mixture of natural polymers andb. an activating agent enhancing the adhesive properties of the natural properties of the natural polymer mixture;this tissue adhesive formulation is particularly useful as a protective, enhanced healing device on the surgical site created during tonsillectomy or adenoidal surgery, as an internal tissue adhesive as a replacement for sutures or staples or as a protective, enhanced healing device for burns, skin grafts or skin donor sites;2. The adhesive material described in where the natural polymers are selected from polysaccharides or partial hydrolysis derivatives or neutralization salts thereof;3. The adhesive material described in where the natural polymers selected are chitosan and an alginate;4. The method of where the natural polymers are chitosan and sodium alginate;5. The adhesive material described in where the activating agent is a dilute aqueous solution of an acid;6. The method of where the acid solution is that of a carboxylic acid;7. The method of where the carboxylic ...

COMPOSITIONS AND METHODS FOR MACROPHAGE CONVERSION

One aspect of the invention provides a method of sequentially inducing macrophage conversion in a wound. The method includes: (a) administering IL-4 to induce conversion of a first population of wound macrophages in the wound to M2A macrophages; and then (b) administering IL-10, dexamethasone, or a dexamethasone analog to induce conversion of a second population of wound macrophages in the wound to M2C macrophages. 1. A method of sequentially inducing macrophage conversion in a wound , the method comprising:(a) administering IL-4 to induce conversion of a first population of wound macrophages in the wound to M2A macrophages; and then(b) administering IL-10, dexamethasone, or a dexamethasone analog to induce conversion of a second population of wound macrophages in the wound to M2C macrophages.2. The method of claim 1 , wherein steps (a) and (b) are sequentially performed by one or more delivery systems.3. The method of claim 2 , wherein the delivery system is a composition selected from the group consisting of: a hydrocolloid composition claim 2 , a hydrogel claim 2 , a polysaccharide-based composition claim 2 , a semi-permeable polymeric adhesive film composition claim 2 , a foam composition claim 2 , a biological composition claim 2 , a polymeric scaffold claim 2 , a sequential controlled-release delivery system claim 2 , and a layer-by-layer delivery system.4. The method of claim 3 , wherein the delivery system comprises IL-4 bound to the delivery system through a binding molecule.5. The method of claim 4 , wherein the binding molecule is non-covalently bound to the delivery system.6. The method of claim 4 , wherein the IL-4 is covalently bound to an affinity molecule that interacts with the binding molecule.7. The method of claim 4 , wherein the IL-4 is released by dissociating the IL-4 from the binding molecule.8. The method of claim 3 , wherein the delivery system comprises IL-10 bound to the delivery system through a binding molecule.9. The method of claim 8 ...

POLYMER-CERAMIC HYBRID FILM HAVING MECHANICAL PROPERTIES AND ELASTICITY, AND METHOD FOR MANUFACTURING SAME

The present invention relates to a polymer-ceramic hybrid film and a method for manufacturing same. The polymer-ceramic hybrid material according to the present invention, which is an elastic polymer-ceramic hybrid film, can maintain a film form for a long time while realizing excellent elasticity and mechanical properties at the same time, and thus can be applied as a medical material such as a patch. Also, a hydrogel used in the manufacturing process of the film can be very usefully utilized as a material for 3D printing. The mechanical strength and elasticity of the polymer-ceramic hybrid film according to the present invention can be improved by varying the arrangement of ceramic particles within the hybrid material by varying the processing process of a hybrid solution. 1. A polymer-ceramic hybrid film comprising:a biocompatible polymer comprising a carboxyl group and a hydroxyl group;calcium phosphate; anda divalent metal ion.2. The polymer-ceramic hybrid film of claim 1 , wherein the biocompatible polymer and the calcium phosphate are mixed at a weight ratio of 20:1 to 8:1.3. The polymer-ceramic hybrid film of claim 1 , wherein the biocompatible polymer and the calcium phosphate are mixed at a weight ratio of 5:1 to 1:1.4. The polymer-ceramic hybrid film of claim 1 , wherein the biocompatible polymer and the calcium phosphate are mixed at a weight ratio of 1:2 to 1:20.5. The polymer-ceramic hybrid film of claim 1 , wherein the biocompatible polymer is alginate.6. The polymer-ceramic hybrid film of claim 5 , wherein a hydroxyl group of the alginate is cross-linked with the calcium phosphate.7. The polymer-ceramic hybrid film of claim 6 , wherein the calcium phosphate is tricalcium phosphate (TCP).8. The polymer-ceramic hybrid film of claim 5 , wherein a carboxyl group of the alginate is cross-linked with the divalent metal ion.9. The polymer-ceramic hybrid film of claim 8 , wherein the divalent metal ion is a calcium ion (Ca).10. The polymer-ceramic hybrid ...

Methods and Compositions for Maintaining the Conformation and Structural Integrity of Biomolecules

A liquid ink composition includes a liquid phase and particles suspended in the liquid phase, the particles containing a target pharmaceutical or biological agent. The biological activity of the target pharmaceutical or biological agent is preserved upon suspension of the particles in the liquid phase. The liquid phase is capable of solidifying via a solidification process. 1. A liquid ink composition comprising:a liquid phase andparticles suspended in the liquid phase, the particles containing a pharmaceutical or biological agent,wherein the biological activity of the pharmaceutical or biological agent is preserved upon suspension of the particles in the liquid phase,wherein the liquid phase is capable of solidifying to form three dimensional structures.2. The liquid ink composition of claim 1 , the particles being formed by a process comprising: a pharmaceutical or a biological agent; and', 'a substrate that is soluble in the solution, comprising one or more chemical species;, 'preparing a solution, formed from water as a solvent, comprisingcombining the solution with an oil phase to form a water-in-oil emulsion in which the solution is dispersed in the oil phase;lyophilizing the emulsion,wherein the particles are formed prior to or simultaneously with the lyophilizing,wherein the pharmaceutical or biological agent is entrapped by the formed particles,wherein the substrate composition and the oil phase are selected so that the particles formed are suspendable in the liquid ink composition and the biological activity of the pharmaceutical or biological agent is preserved upon suspension of the particles in the liquid ink composition, andwherein one or more substances selected from the group consisting of a surfactant, a stabilizer, an emulsifier, and combinations thereof are incorporated as part of the substrate.3. The liquid ink composition of claim 1 , wherein the biological activity of the pharmaceutical or biological agent is preserved upon solidification of ...

INTERPENETRATING POLYMER NETWORK HYDROGEL

An interpenetrating polymer network (IPN) structured hydrogel includes a crosslinked first natural polymer macromer with a first elasticity and an interpenetrating network of crosslinked second natural polymer macromers having a second elasticity higher than the first elasticity, the IPN structured hydrogel being cytocompatible, and, upon degradation, produce substantially non-toxic products. 1. A composition comprising:an interpenetrating polymer network (IPN) structured hydrogel that includes a crosslinked first natural polymer macromer with a first elasticity and an interpenetrating network of crosslinked second natural polymer macromers having a second elasticity higher than the first elasticity, the IPN structured hydrogel being cytocompatible, and, upon degradation, produce substantially non-toxic products.2. The composition of claim 1 , wherein the elasticity of the hydrogel is substantially maintained during degradation.3. The composition of claim 1 , wherein the first natural polymer macromers are crosslinked with a first agent and the second natural polymer macromer are crosslinked with a second agent different than the first agent.4. The composition of claim 3 , wherein the first agent crosslinks the first natural polymer macromers but not the second natural polymer macromers claim 3 , and the second agent crosslinks the second natural polymer macromers but not the first natural polymer macromers.5. The composition of claim 3 , wherein the first natural polymer macromers are polysaccharides claim 3 , which are optionally oxidized.6. The composition of claim 5 , wherein the first natural polymer macromers comprise oxidized alginates7. The composition of claim 5 , wherein the first natural polymer macromers are ionically crosslinkable with the first agent.8. The composition of claim 3 , wherein the second natural polymer macromers comprise acrylated and/or methacrylated gelatin.9. The composition of claim 8 , wherein the second natural polymer macromers are ...

LOW GSM FIBER WEB AND METHOD OF MAKING SAME

A light-weight fabric and method for producing the fabric, the method comprising providing a selected mass of starting material comprising fibers of the starting material, the fibers being in the range of about 5 cm to 30 cm in length and orienting the fibers in the selected mass to produce a loose web of fibers. The fibers in the loose web of fibers are mechanically attached or felted to provide structural integrity to the web and thus tighten the web of fibers into the fabric. The fabric is light weight and thus less than approximately 100 GSM in weight, more specifically less than approximately 50 GSM and may even be about approximately 25 GSM. The fabric can be used in wound care dressings. 1. A method for producing a fabric , the method comprising:providing a selected mass of starting material comprising fibers of the starting material, the fibers being in the range of about 5 cm to about 30 cm in length;orienting the fibers in the selected mass to produce a loose web of fibers; andmechanically attaching the fibers to provide structural integrity to the web and thus tighten the web of fibers into the fabric,wherein the fabric is less than approximately 100 GSM in weight.2. The method of claim 1 , wherein the starting material is provided in continuous strands of fibers and the fibers are cut or chopped to lengths in the range of about 5 cm to about 30 cm.3. The method of wherein orienting the fibers comprises providing the selected mass of starting material to a carding machine to produce the loose web of fibers.4. The method of wherein mechanically attaching the fibers comprises felting the loose web of fibers.5. The method of claim 1 , wherein the selected mass has a weight that is substantially equal to the GSM weight of the produced fabric.6. The method of claim 5 , the GSM weight of the fabric is less than approximately 75 GSM.7. The method of claim 5 , the GSM weight of the fabric is less than approximately 30 GSM.8. The method of claim 1 , and further ...

DEPOLYMERISATION OF ALGINIC ACID

Depolymerisation of alginic acid by microwave treatment. 1. A method of depolymerisation of alginic acid , said method comprising the steps of:(a) providing alginic acid as a starting material for step b, wherein the alginic acid starting material has a pH in the range of 0-4.4 and wherein the dry matter content of the alginic acid starting material is in the range of 15-70% w/w, and(b) treating said alginic acid starting material with microwave irradiation to obtain a depolymerised alginic acid material.2. The method according to claim 1 , wherein the microwave frequency is between 300 MHz and 300 GHz.3. The method according to claim 1 , wherein the concentration of alginic acid in the alginic acid starting material is in the range of 7.5-100% w/w based on dry matter.4. The method according to claim 1 , wherein the alginic acid starting material has a pH in the range of 0-3.5.5. (canceled)6. The method according to claim 1 , wherein the starting alginic acid material has a weight average molecular weight of 1 claim 1 ,500 claim 1 ,000-50 claim 1 ,000 Da.7. The method according to claim 1 , wherein the alginic acid starting material comprises alginic acid in a mixture with one or more solvents selected from the group consisting of water claim 1 , methanol claim 1 , ethanol claim 1 , and isopropanol.8. The method according to claim 1 , wherein the alginic acid starting material comprises alginic acid in water.9. The method according to claim 1 , wherein the alginic acid starting material further comprises a reducing and/or oxidizing agent.10. The method according to claim 1 , wherein the alginic acid starting material is drained and/or pressed and/or dried before the microwave treatment.11. The method to according to claim 1 , wherein the depolymerised alginic acid material has a weight average molecular weight of 300 claim 1 ,000-2 claim 1 ,000 Da.12. The method according to claim 1 , wherein the depolymerised alginic acid material is further neutralised after the ...

COACERVATE MICRO AND/OR NANO DROPLETS AND HYDROGELS

A composition includes a plurality of coacervate micro and/or nanodroplets of oxidized alginate and a methacrylated gelatin. 120-. (canceled)21. A method for promoting tissue growth in a subject comprising:administering a coacervate hydrogel to a target site in the subject, the coacervate hydrogel comprising: crosslinked oxidized alginate and methacrylated gelatin that form a hydrogel matrix and a plurality of coacervate microdroplets and/or nanodroplets suspended in the matrix, wherein the oxidized alginate has an oxidation percentage of at least 10% of uronic acid units of alginate and the methacrylated gelatin has a methacrylation percentage of about 10% to about 99% of amine groups of gelatin.22. The method of claim 21 , wherein at least one bioactive agent is incorporated in the coacervate microdroplets and/or nanodroplets and/or matrix.23. The method of claim 21 , wherein the oxidized alginate has an oxidation percentage of up to 50% of uronic acid units of alginate.24. The method of claim 21 , wherein the oxidized alginate is methacrylated and has a methacrylation percentage up to 45% of alginate carboxylic acid reactive groups.25. The method of claim 22 , wherein the hydrogel matrix includes a plurality of cells and the plurality of coacervate microdroplets and/or nanodroplets provide controlled release of the bioactive agent to the plurality of cells.26. The method of claim 25 , wherein the bioactive agent comprises BMP-2 and the cells comprise hMSCs.27. The method of claim 21 , wherein the coacervate hydrogel is administered to a tissue defect.28. The method of claim 27 , wherein the tissue defect is a bone and/or cartilage defect.29. A method for promoting tissue growth in a subject comprising:administering a coacervate hydrogel to a target site in the subject, the coacervate hydrogel comprising: a crosslinked oxidized methacrylated alginate and a methacrylated gelatin that form a hydrogel matrix and a plurality of coacervate microdroplets and/or ...

SCAFFOLD FOR CARDIAC PATCH

A biocompatible and biodegradable medical device patch actuating primarily as soft tissue structural reinforcement. The device has a layered architecture, where the primary serves as suturing layer and mechanical support to a thick porous scaffold which can be coated with a mimic-like extra cellular matrix (ECM). The device can be provided to the end user under the format of independent layers that can be cut and assembled to the specific need to the end user and patient. The layers are assembled without the need of any adhesive. Totally haemocompatible and of behavior superior to polytetrafluoroethylene used for any soft tissue repaired, the field of this invention is demonstrated for cardiovascular therapy but should not be limited to it. It is of practical relevance of vein, tendon and hernias and dermal treatments. 1. A composition comprising a hydrogel formed using one or more self-assembling peptides , wherein the self-assembling peptides:a) are 8 to 12 amino acid residues in length;b) terminates in one or more K residues;c) have an at least 5 amino acid sequence upstream of the K residue where every other amino acid residue is the same amino acid residue of a first type.2. The composition as claimed in claim 1 , wherein the amino acid residue of the first type is an F or V residue.3. The composition as claimed in claim 2 , wherein a self-assembling peptide terminates in KXK claim 2 , where X is selected from F or V residues.4. The composition as claimed in claim 1 , wherein every other intervening amino acid residue is the same amino acid residue of a second type.5. The composition as claimed in claim 4 , wherein the amino acid residue of the second type is an E residue.6. The composition as claimed in claim 1 , wherein the self-assembling peptides are selected from the sequences SEQ ID NO: 1 claim 1 , SEQ ID NO: 2 claim 1 , SEQ ID NO: 3 claim 1 , SEQ ID NO: 4 claim 1 , and combinations thereof.7. The composition as claimed in claim 1 , wherein the ...

Decellularization and recellularization of whole organs

The present invention provides systems and methods for the decellularization and recellularization of tissue segments. In certain instances the invention comprises coating or sealing decellularized tissue segments with a cross-linked alginate hydrogel. The present invention also provides a decellularization kit, which may be used to generate decellularized tissue segments for high throughput studies. Also included are compositions and methods of tissue sealants comprising methacrylated alginate.

Dendritic Macroporous Hydrogels Prepared By Crystal Templating

The present invention includes a hydrogel and a method of making a porous hydrogel by preparing an aqueous mixture of an uncrosslinked polymer and a crystallizable molecule; casting the mixture into a vessel; allowing the cast mixture to dry to form an amorphous hydrogel film; seeding the cast mixture with a seed crystal of the crystallizable molecule; growing the crystallizable molecule into a crystal structure within the uncrosslinked polymer; crosslinking the polymer around the crystal structure under conditions in which the crystal structure within the crosslinked polymer is maintained; and dissolving the crystals within the crosslinked polymer to form the porous hydrogel. 1. A hydrogel that comprises molecular pores, the hydrogel comprising: one or more crosslinked polymers formed about a plurality of pre-formed molecular crystals, wherein the crystals are formed while the polymer is in an uncrosslinked form and the molecular crystals form a porous structure within the polymers during the crosslinking of the polymers. This application is a continuation of U.S. patent application Ser. No. 15/890,719, filed Feb. 7, 2018, which is a continuation of U.S. patent application Ser. No. 15/135,978, filed Apr. 22, 2016, now U.S. Pat. No. 9,896,561, issued Feb. 20, 2018, which is a continuation of U.S. patent application Ser. No. 14/277,170, filed May 14, 2014, now U.S. Pat. No. 9,320,827, issued Apr. 26, 2016, which is a continuation of U.S. patent application Ser. No. 13/909,707, filed Jun. 4, 2013, now U.S. Pat. No. 8,728,499, issued May 20, 2014, which is a continuation of U.S. patent application Ser. No. 12/919,667, filed Aug. 26, 2010, now U.S. Pat. No. 8,668,863, issued Mar. 11, 2014, which claims priority to Patent Cooperation Treaty Application Serial No. PCT/US2009/035257, filed Feb. 26, 2009, which claims priority to U.S. Provisional Patent Application Ser. No. 61/031,651, filed Feb. 26, 2008 and entitled “DENDRITIC MACROPOROUS HYDROGELS PREPARED BY CRYSTAL ...

Compositions and methods for modifying in vivo calcification of hydrogels

Provided herein according to some embodiments of the invention are methods of inhibiting or preventing calcification of hydrogels. Such methods may include combining the hydrogel with a buffer solution having a pH lower than 7.4; forming hydrogel by crosslinking alginate in a solution comprising a bisphosphonate compound; and/or forming hydrogel by crosslinking polyanionic polymer with a polyvalent cation that is not Ca 2+ . Compositions that may be used in such methods are also provided herein. Also provided herein according to some embodiments of the invention are methods of bone regeneration and/or formation that include administering hydrogel that does not encapsulate biological material that affects calcification and/or bone formation to an area of a subject's body that is in need of bone formation and/or regeneration.

Compositions and methods for cardiac therapy

Provided herein are methods and compositions for cardiac therapy. Such compositions include extracellular-matrix (ECM)-based products that can be used to support tissue repair. The compositions can be used for various purposes. In some cases, they can be introduced into a subject in order to preserve and/or repair damaged heart tissue.

HIGHLY-SWELLABLE POLYMERIC FILMS AND COMPOSITIONS COMPRISING THE SAME

Highly-swellable polymeric films are provided. Aspects also include ingestible compositions that include the highly-swellable polymeric film and an ingestible component. Aspects further include methods of making and using the compositions. 139.-. (canceled)40. A device comprising:a framework;a control device coupled to the framework;a partial power source coupled to the control device and configured to provide power to the control device when activated, the partial power source comprising an anode material and a cathode material; anda highly-swellable polymeric film that rapidly swells without disintegrating upon contact with an aqueous medium external to the device, and covers at least one of the anode material and the cathode material;{'claim-text': ['in a first mode of operation, increase shelf-life stability of the device by inhibiting reaction of at least one of the anode material and the cathode material with ambient moisture while the device is in storage; and', {'claim-text': ['swell upon contact with the aqueous medium; and', 'upon swelling, provide conduction between the aqueous medium and at least one of the anode material and the cathode material that the highly-swellable polymeric film is covering.'], '#text': 'in a second mode of operation:'}], '#text': 'wherein the highly-swellable polymeric film is pre-fabricated to:'}41. The device according to claim 40 , wherein the highly-swellable polymeric film rapidly swells to ten times or greater in volume upon contact with the aqueous medium.42. The device according to claim 41 , wherein the highly-swellable polymeric film swells to ten times or greater in volume within one minute or less upon contact with the aqueous medium.43. The device according to claim 40 , wherein the highly-swellable polymeric film is configured to absorb ten grams or more of water per gram of film upon contact the aqueous medium.44. The device according to claim 40 , wherein the highly-swellable polymeric film comprises an ionic ...

INJECTABLE PREFORMED MACROSCOPIC 3-DIMENSIONAL SCAFFOLDS FOR MINIMALLY INVASIVE ADMINISTRATION

The invention provides polymer compositions for cell and drug delivery. 128-. (canceled)29. An injectable cell-compatible highly crosslinked cryogel polymer composition comprising open interconnected pores ,wherein the cryogel comprises at least 75% pores;wherein the cryogel polymer composition is characterized by shape memory following deformation by compression or dehydration; andwherein the cryogel composition comprises a crosslinked gelatin polymer or a crosslinked alginate polymer.30. The cryogel polymer composition of claim 29 , wherein the cryogel composition is characterized by shape memory following deformation by compression through a needle.31. The cryogel polymer composition of claim 29 , further comprising a biomolecule.32. The cryogel polymer composition of claim 31 , wherein the biomolecule comprises a small molecule claim 31 , a nucleic acid claim 31 , or a protein.33. The cryogel polymer composition of claim 32 , wherein the biomolecule is a protein that recruits a cell into the cryogel composition upon injection into a subject.34. The cryogel polymer composition of claim 33 , wherein the protein is GM-CSF.35. The cryogel polymer composition of claim 33 , wherein the cell is an immune cell.36. The cryogel polymer composition of claim 35 , wherein the immune cell is a dendritic cell.37. The cryogel polymer composition of claim 29 , further comprising an adjuvant.38. The cryogel polymer composition of claim 37 , wherein the adjuvant is cytosine-guanosine oligonucleotide (CpG-ODN).39. The cryogel polymer composition of claim 29 , wherein the gelatin or alginate is acrylated or methacrylated.40. The cryogel polymer composition of claim 39 , wherein the alginate is a methacrylated alginate macromonomer with a concentration of about 1% (w/v).41. The cryogel polymer composition of claim 29 , wherein the cryogel composition is characterized by at least 50% polymer crosslinking.42. The cryogel polymer composition of claim 41 , wherein the cryogel composition ...

CHITIN AND ALGINATE COMPOSITE FIBERS

Disclosed herein are composite fibers that comprises chitin and alginate. The formation of the chitinous-alginate composite fiber involves the use of ionic liquids and high molecular weight pure chitin obtained directly from chitin biomass. Optional additive such as vitamin E is successfully incorporated in to the composite fiber. The chitinousalginate fiber formed has a continuous and homogenous morphology, even with the addition of additive. Methods of making and using the chitinous-alginate composite fiber as wound dressing is also disclosed. 1. A composite fiber comprising at least 80% by weight of combined chitinous and alginate components in a predetermined ratio having a continuous and homogenous morphology.2. The composite fiber of claim 1 , wherein the weight ratio between the chitinous component and the alginate component is at least 2:1.3. The composite fiber of claim 1 , wherein the weight ratio between the chitinous component and the alginate component is at least 3:1.4. The composite fiber of claim 1 , wherein the weight ratio between the chitinous component and the alginate component is at least 4:1.5. The composite fiber of claim 1 , wherein the composite fiber further comprising an additive.6. The composite fiber of claim 1 , wherein the additive is vitamins claim 1 , nutraceuticals claim 1 , non-steroidal anti-inflammatory drugs claim 1 , anesthetics claim 1 , analgesics claim 1 , or ionic liquid active pharmaceutical ingredients.7. The composite fiber of claim 1 , wherein the additive is vitamin E that is about 10% by weight of the composite fiber and the combined chitin and alginate component is about 90% by weight of the composite fiber.8. The composite fiber of claim 1 , wherein the linear mass density of the composite fiber is at least 10 times of the linear mass density of alginate fibers.9. The composite fiber of claim 1 , wherein the moisture content of the composite fiber is at least 50% less than the moisture content of alginate fibers.10 ...

Polymeric Carriers and Methods

Provided are methods of controlling disassociation of cells from a carrier, compositions, and methods of collecting cells. The methods of controlling disassociation of cells from a carrier may include contacting a polymeric carrier with one or more digesting agents to disassociate at least a portion of a plurality of cells from the polymeric carrier. The polymeric carrier may be crosslinked with a crosslinker including at least one of a redox sensitive moiety, a UV light sensitive moiety, a pH sensitive moiety, and a temperature sensitive moiety. 1. A method of controlling disassociation of cells from a carrier , the method comprising:providing a polymeric carrier and a plurality of cells adhered to the polymeric carrier; andcontacting the polymeric carrier with one or more digesting agents to disassociate at least a portion of the plurality of cells from the polymeric carrier;wherein the polymeric carrier is crosslinked with a crosslinker comprising at least one redox sensitive moiety.2. The method of claim 1 , wherein the at least one redox sensitive moiety comprises a disulfide bond.13. A method of controlling disassociation of cells from a carrier claim 1 , the method comprising:providing a polymeric carrier and a plurality of cells adhered to the polymeric carrier; andcontacting the polymeric carrier with one or more digesting agents to disassociate at least a portion of the plurality of cells from the polymeric carrier;wherein the polymeric carrier is crosslinked with a crosslinker comprising at least one of a UV light sensitive moiety, a pH sensitive moiety, and a temperature sensitive moiety.14. The method of claim 13 , wherein the crosslinker comprises the UV light sensitive moiety claim 13 , and the UV light sensitive moiety is a photoreversibly dimerizable moiety or a photocleavable moiety.19. The method of claim 14 , wherein the crosslinker comprises the photocleavable moiety claim 14 , and the photocleavable moiety comprises an o-nitrobezene based ...

NERVE REGENERATION-INDUCING MATERIAL

A non-tubular material for nerve regeneration induction, which can be used for the regeneration of a damaged part in a nerve, and which comprises: (A) a crosslinked form produced by crosslinking a low-endotoxin bioabsorbable polysaccharide having a carboxyl group in the molecule with at least one crosslinkable reagent selected from a compound represented by general formula (I) and a salt thereof via covalent bonds; and (B) a bioabsorbable polymer. RHN—(CH)—NHR(I) [wherein Rand Rindependently represent a hydrogen atom or a group represented by formula: —COCH(NH)—(CH)—NH, and n represents an integer of 2 to 18]. Thus, a medical material that can induce the regeneration of a damaged part in a nerve is provided. 2. The nerve regeneration-inducing material according to claim 1 , wherein the bioabsorbable polysaccharide having a carboxyl group in a molecule thereof is at least one type selected from the group consisting of alginic acid claim 1 , an ester thereof and a salt thereof.3. The nerve regeneration-inducing material according to claim 1 , wherein the crosslinking reagent is an N-hydroxysuccinimide salt of the compound represented by general formula (I).4. The nerve regeneration-inducing material according to claim 3 , wherein the N-hydroxysuccinimide salt of the compound represented by general formula (I) is at least one type selected from the group consisting of a 2N-hydroxysuccinimide salt of diaminoethane claim 3 , a 2N-hydroxysuccinimide salt of diaminohexane claim 3 , a 4N-hydroxysuccinimide salt of N claim 3 ,N′-di(lysyl)-diaminoethane and a 3N-hydroxysuccinimide salt of N-(lysyl)-diaminohexane.5. The nerve regeneration-inducing material according to claim 1 , which is in the form of a xerogel.6. The nerve regeneration-inducing material according to claim 1 , wherein the bioabsorbable polymer is at least one type selected from the group consisting of polyglycolic acid claim 1 , polylactic acid and a copolymer thereof claim 1 , and polycaprolactone.7. The ...

HYDROGEL ENCAPSULATED CELLS AND ANTI-INFLAMMATORY DRUGS

A composition containing biocompatible hydrogel encapsulating mammalian cells and anti-inflammatory drugs is disclosed. The encapsulated cells have reduced fibrotic overgrowth after implantation in a subject. The compositions contain a biocompatible hydrogel having encapsulated therein mammalian cells and anti-inflammatory drugs or polymeric particles loaded with anti-inflammatory drugs. The anti-inflammatory drugs are released from the composition after transplantation in an amount effective to inhibit fibrosis of the composition for at least ten days. Methods for identifying and selecting suitable anti-inflammatory drug-loaded particles to prevent fibrosis of encapsulated cells are also described. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject. 1. A composition comprisinga biocompatible hydrogel having encapsulated therein(a) one or more mammalian secretory, metabolic or structural cells; and(b) one or more anti-inflammatory drugs bound within or to the composition, encapsulated in or on polymeric particles dispersed on or within the biocompatible hydrogel, or a combination thereof;wherein the anti-inflammatory drug is released from the composition after implantation in a mammalian subject in an amount effective to prevent detectable fibrosis of the composition for at least 10 days, more preferably 14, 30, 60, or 90 days.2. The composition of claim 1 , comprising(a) a core comprising a biocompatible hydrogel,(b) an envelope comprising a biocompatible hydrogel, and(c) optionally a membrane separating the core and the envelope,wherein the one or more mammalian cells are encapsulated in the core,wherein the anti-inflammatory drugs or drug-loaded polymeric particles are encapsulated within the envelope, within the core, or within the envelope and the core.3. The composition of claim 2 , wherein the membrane comprises polycation crosslinked ...

Novel crosslinked alginic acid

The present invention provides alginic acid derivatives represented by formula (I) and formula (II), and a novel crosslinked alginic acid obtained by carrying out a Huisgen reaction using an alginic acid derivative of formula (I) and an alginic acid derivative of formula (II). There are thereby provided novel alginic acid derivatives and a novel crosslinked alginic acid.

METHOD FOR MANUFACTURING WATER-INSOLUBLE MOLDED ARTICLE AND WATER-INSOLUBLE MOLDED ARTICLE

A process for producing a water-insoluble shaped material, including a step of treating a raw material shaped material containing a water-soluble salt of a polyanionic polysaccharide with a treatment liquid containing an acid anhydride to insolubilize the raw material shaped material in water, and the process makes it possible to simply produce a water-insoluble shaped material in which intrinsic characteristics of the polyanionic polysaccharide being a raw material are retained, which has a high safety in that a chemical crosslinking agent is not required, and which is useful as a medical material, a food material, a cosmetic material, and the like. 116-. (canceled)17. A water-insoluble shaped material , comprising polyanionic polysaccharide in an acid form , wherein the treating converts the water-soluble salt of the polyanionic polysaccharide to the polyanionic polysaccharide in an acid form, and', 'the acid anhydride does not form a covalent bond with the polyanionic polysaccharide in the acid form., 'wherein the water-insoluble shaped material is produced by a process comprising: treating a raw material shaped material that comprises a water-soluble salt of the polyanionic polysaccharide, with a treatment liquid comprising an acid anhydride so as to insolubilize the raw material shaped material in water and form the water-insoluble shaped material,'}18. The water-insoluble shaped material according to claim 17 ,wherein the water-insoluble shaped material is dissolved in an aqueous medium having a pH of 12 or higher.19. The water-insoluble shaped material according to claim 17 , being a medical material claim 17 , a food material claim 17 , or a cosmetic material. The present invention relates to a process for producing a water-insoluble shaped material, and also relates to a water-insoluble shaped material, an adhesion inhibitor, an injection material, and a sustained release preparation.It is known that polyanionic polysaccharides such as hyaluronic acid and ...

COATED COMPOSITE MATERIAL

An object of the present invention is to provide a composite material that may be easily delivered and mounted in the living body. The object can be solved by a coated composite material characterized in that a composite material, in which a porous body is bounded to a substrate, is coated with at least one soluble component selected from a group consisting of a water-soluble compound, a temperature-sensitive soluble compound, and a pH sensitive soluble compound. 1. A coated composite material characterized in that a composite material in which a porous body is bounded to a substrate , is coated with at least one soluble component selected from a group consisting of a water-soluble compound , a temperature-sensitive soluble compound , and a pH sensitive soluble compound.2. The coated composite material according to claim 1 , wherein the pH sensitive soluble compound is a weakly acidic or neutral soluble compound claim 1 , an acidic soluble compound claim 1 , or an alkaline soluble compound.3. The coated composite material according to claim 1 , wherein a water content ratio of the coated composite material is 20% or less by weight.4. The coated composite material according to claim 1 , wherein the water-soluble compound is selected from a group consisting of starch claim 1 , polyethylene glycol claim 1 , glycerogelatin claim 1 , pullulan claim 1 , pectin claim 1 , carrageenan claim 1 , β-glucan claim 1 , vinyl ester based polymer claim 1 , alginic acid claim 1 , alginic acid derivative claim 1 , collagen claim 1 , collagen hydrolyzate claim 1 , furcellaran claim 1 , silume seed gum claim 1 , cassia gum claim 1 , fenugreek gum claim 1 , quince seed gum claim 1 , tarabine gum claim 1 , almond gum claim 1 , damson gum claim 1 , arabinogalactan claim 1 , dextran claim 1 , rhamsan gum claim 1 , levan claim 1 , azotobacter vinelandii gum claim 1 , enterobacter gum claim 1 , welan gum claim 1 , and a combination of two or more thereof claim 1 , the temperature-sensitive ...

ALGINATE HYDROGEL COMPOSITIONS

The present application provides a semi-permeable hydrogel composition comprising an alginate matrix that is covalently crosslinked in its periphery to a multi-armed water soluble polymer, along with related methods and uses thereof. 1. A semi-permeable hydrogel composition comprising an alginate matrix covalently crosslinked in the periphery of the alginate matrix to a multi-armed water soluble polymer.2. The semi-permeable hydrogel composition of claim 1 , wherein the multi-armed water soluble polymer penetrates the periphery of the alginate matrix.3. The semi-permeable hydrogel composition of claim 1 , wherein the periphery of the alginate matrix is interlocked with and covalently crosslinked to the multi-armed water soluble polymer.4. The semi-permeable hydrogel composition of claim 1 , wherein the hydrogel composition further comprises 1-20 surface layers of alginate that is covalently crosslinked to a multi-armed water soluble polymer.5. The semi-permeable hydrogel composition of claim 1 , wherein the hydrogel composition further comprises a biocompatible surface layer claim 1 , wherein the biocompatible surface layer is covalently bonded to the semi-permeable hydrogel composition.6. (canceled)7. The hydrogel composition of claim 1 , wherein the hydrogel composition is stable for at least 30 days at 40° C. in 1 mM phosphate buffered saline.8. (canceled)9. The hydrogel composition of claim 7 , wherein the composition is characterized by a first tan delta value determined at the time the composition is subjected to storage at 40° C. in 1 mM phosphate buffered saline (day 0) claim 7 , and a second tan delta value determined after the composition has been stored for 30 days at 40° C. in 1 mM phosphate buffered saline; and wherein the first tan delta value and the second tan delta value are the same or differ by no more than about 0.05.10. The hydrogel composition of claim 7 , wherein the hydrogel maintains its semi-permeability after storage for 30 days at 40° C. ...

SPRAYABLE BARRIER AND METHODS FOR PREVENTION OF POSTOPERATIVE ADHESIONS

Biologically acceptable surgical barrier materials are comprised of a polyelectrolytic complex of chitosan and sodium alginate. The chitosan is deacetylated in an amount between about 40 to about 60% and has a molecular weight (Mw) between 50,000 and 375,000 g/mol. The barrier materials may be formed by mixing a two-component material system whereby one component comprises the chitosan and a second component comprises the sodium alginate and directing such a mixture (e.g., via air-assisted spray nozzle) toward a surgical site in need of the material. A polyelectrolytic complex of the chitosan and sodium alginate will thereby form in situ. Suitable ionic cross-linkers may be provided in the individual components, e.g., calcium chloride with the chitosan component and sodium tripolyphosphate with the sodium alginate component. 1. A biologically acceptable surgical barrier material comprised of a polyelectrolytic complex of chitosan and sodium alginate.2. The material of claim 1 , wherein the chitosan is deacetylated in an amount between about 40 to about 60%.3. The material of claim 2 , wherein the chitosan has a molecular weight (Mw) between 50 claim 2 ,000 and 375 claim 2 ,000 g/mol.4. The material of claim 1 , further comprising an ionic crosslinker.5. The material of claim 4 , wherein the ionic crosslinker is selected from the group consisting of calcium chloride and sodium tripolyphosphate.6. The material as in claim 1 , which further comprises a colorant.7. A sprayable biologically acceptable surgical barrier material system comprised of a first component comprising chitosan and a second component comprising sodium alginate claim 1 , wherein mixing of the first and second components forms a polyelectrolytic complex of the chitosan and sodium alginate.8. The material system of claim 7 , wherein the chitosan is deacetylated in an amount between about 40 to about 60%.9. The material system of claim 8 , wherein the chitosan has a molecular weight (Mw) between 50 ...

Absorbent material

This invention relates to absorbent materials useful in the manufacture of absorbent articles, in particular dressings for the advanced wound care market. The absorbent materials of the present invention are sulfonated polysaccharides, particularly water-insoluble cellulose alkyl sulfonates in which the cellulose is substituted by one type of alkyl sulfonate group. The invention also provides a process for the manufacture of such materials. The preferred cellulose alkyl sulfonate described herein is cellulose ethyl sulfonate. Reinforcing fibers and/or antimicrobial agents are optionally applied to the cellulose alkyl sulfonate.

Method of Preparation of Polysaccharide Fibres, Wound Covers that Contain Them, Method of Manufacturing of Wound Covers, and Apparatus for Preparation of Polysaccharide Fibres

The invention relates to the method of the preparation of polysaccharide fibers based on hyaluronic acid, a compound comprising hyaluronic acid and metal ions, schizophylan, chitin/chitosan-glucan complex, a compound comprising chitin/chitosan-glucan complex and metal ions, internal mixture of chitin and chitosan, a compound comprising internal mixture of chitin and metal ions, sodium alginate, potassium alginate, ammonium alginate, xanthane, xanthane sodium salt, xanthane potassium salt, oxycellulose, oxycellulose sodium salt, oxycellulose potassium salt, carboxymethyl cellulose, carboxymethyl cellulose sodium salt, and carboxymethyl cellulose potassium salt, or a mixture of polysaccharides, in a non-stationary coagulation bath. Further the invention relates to covers of internal and external wounds and skin defects based on these fibers, and a method of production thereof, and the apparatus for the preparation of polysaccharide fibers.

ELASTOMERIC NANOCOMPOSITE HYDROGELS

An elastomeric nanocomposite hydrogel includes first natural polymer macromers covalently crosslinked with second natural polymer macromer and physically crosslinked with a plurality of inorganic nanoparticles. The elastomeric nanocomposite hydrogel is cytocompatible, and, upon degradation, produce substantially non-toxic products. 1. A composition comprising:an elastomeric nanocomposite hydrogel that includes first natural polymer macromers covalently crosslinked with second natural polymer macromer and physically crosslinked with a plurality of inorganic nanoparticles, the elastomeric nanocomposite hydrogel being cytocompatible, and, upon degradation, produce substantially non-toxic products.2. The composition of claim 1 , wherein the elasticity of the hydrogel is substantially maintained during degradation.3. The composition of claim 1 , wherein the first natural polymer macromers are photocrosslinked with the second natural polymer macromers.4. The composition of claim 3 , wherein the first natural polymer macromers are acrylated and/or methacrylated polysaccharides claim 3 , which are optionally oxidized.5. The composition of claim 5 , wherein the first natural polymer macromers comprise acrylated and/or methacrylated alginates claim 5 , which are optionally oxidized.6. The composition of claim 5 , wherein the first natural polymer macromers form reversible physical crosslinks with the inorganic nanoparticles.7. The composition of claim 1 , wherein the second natural polymer macromers comprise acrylated and/or methacrylated gelatin.8. The composition of claim 1 , wherein the first natural polymer macromers comprise optionally oxidized acrylated and/or methacrylated polysaccharides and the second natural polymer macromers comprise acrylated and/or methacrylated gelatin and wherein methacrylate and/or acrylate groups of the optionally oxidized acrylated and/or methacrylated polysaccharides react with methacrylate and/or acrylate groups of the acrylated and/or ...

BIOINK AND CROSSLINKABLE SUPPORT MEDIUM FOR PRINTING

A system for forming a scaffold-free 3D tissue construct includes a three dimensional (3D) printer; a self-healing, shear thinning, crosslinkable, biocompatible hydrogel support medium; and a first bioink that includes a plurality of cells. The first bioink is capable of being printed with the 3D printer into the hydrogel support medium in a defined shape. 1. A method for forming a scaffold-free 3D tissue construct comprising:providing a self-healing, shear thinning, crosslinkable, biocompatible hydrogel support medium;printing a first bioink into the hydrogel support medium, the first bioink including a plurality of cells and optional macromer carrier, nanoparticles, microparticles, bioactive agents, cell aggregates, and/or organoids, the printed first bioink having a defined shape; andculturing the printed plurality of cells and optional macromer carrier, nanoparticles, microparticles, bioactive agents, cell aggregates, and/or organoids in the hydrogel support medium to form a cell aggregate or tissue construct with the defined shape.2. The method of claim 1 , wherein the hydrogel support medium maintains the defined shape of the printed first bioink during printing and optionally culturing.3. The method of claim 1 , wherein the hydrogel support medium behaves as a viscous fluid during printing and as is resistant to flow before and after printing.4. The method of claim 1 , further comprising crosslinking the hydrogel support medium printed with the first bioink to enhance the mechanical stability of the hydrogel support medium.5. The method of claim 4 , further comprising separating the printed construct from the hydrogel support medium.6. The method of claim 1 , wherein the hydrogel support medium comprises a plurality of hydrogel particles that include a plurality of crosslinkable biodegradable natural polymer macromers.7. The method of claim 5 , the hydrogel particles having an average diameter of about 10 nm to about 10 mm.8. The method of claim 6 , wherein ...

COMPOSITIONS, DEVICES, AND METHODS FOR TREATING FABRY DISEASE

Described herein are RPE cells engineered to secrete a GLA protein, as well as compositions, pharmaceutical preparations, and implantable devices comprising the engineered RPE cells, and methods of making and using the same for treating Fabry disease. 1. An engineered mammalian cell capable of expressing and secreting an alpha-galactosidase A (GLA) protein , wherein the cell comprises an exogenous nucleotide sequence comprising a promoter operably linked to a precursor GLA coding sequence having one or more of the following features:(a) the precursor GLA coding sequence is codon-optimized for expression in the mammalian cell; (i) a signal peptide from a secretory protein other than GLA operably linked to the N-terminus of a mature human GLA amino acid sequence; or', '(ii) a GLA fusion protein which comprises a signal peptide operably linked to the N-terminus of a mature human GLA amino acid sequence, and an amino acid sequence encoding a non-GLA polypeptide operably linked to the C-terminus of the GLA amino acid sequence; and', 'wherein the mammalian cell is derived from a retinal epithelial cell transfected with a transcription unit comprising the exogenous nucleotide sequence., '(b) the precursor GLA coding sequence encodes a GLA fusion protein, which comprises2. The engineered cell of claim 1 , wherein the promoter comprises SEQ ID NO:18.3. The engineered cell of claim 1 , wherein the precursor GLA coding sequence comprises SEQ ID NO:3 or SEQ ID NO:4.4. The engineered cell of claim 1 , wherein the signal peptide is from a mammalian HSPG2 protein.5. The engineered cell of claim 4 , wherein the precursor GLA coding sequence comprises SEQ ID NO:16.6. The engineered cell of claim 1 , wherein the GLA fusion protein comprises SEQ ID NO: 5 claim 1 , SEQ ID NO:7 claim 1 , SEQ ID NO:11 claim 1 , or SEQ ID NO:13.7. The engineered cell of claim 6 , wherein the precursor GLA coding sequence comprises SEQ ID NO:6 claim 6 , SEQ ID NO:9 claim 6 , SEQ ID NO:12 or SEQ ID NO:14.8. ...

SHEAR-THINNING HYDROGEL, KIT AND METHOD OF PREPARATION

A shear-thinning hydrogel composition includes: a first polymer chain including: (i) a first plurality of units each having at least one of a monosaccharide and an amino acid; and (ii) a cross-linking group bound to the at least one of the monosaccharide and the amino acid of one of the first plurality of units via conversion of a carboxyl group of the unit to a peptide bond; a second polymer chain including a second plurality of the units; and a cross-linking additive connecting one of the second plurality of units to the first polymer chain via the cross-linking group. 123-. (canceled)24. A kit comprising: (i) a first plurality of units of hyaluronic acid, each unit having at least one monosaccharide; and', '(ii) a further plurality of units of alginate bound to the first plurality of units; and', '(iii) a cross-linking group comprising dopamine bound to the at least one monosaccharide of one of the first plurality of units via conversion of a carboxyl group of the unit to a peptide bond; and, 'a quantity of a powdered polymer including collagen and a first polymer chain, the first polymer chain includinga quantity of a cross-linking additive comprising a 2+ charged ion for connecting first and second chains of the polymer via the cross-linking group, the second chains of the polymer including a second plurality of the units, the cross-linking additive connecting one of the second plurality of units to the first polymer chain via the cross-linking group.25. The kit of claim 24 , wherein the quantity of the powdered polymer includes:a first quantity of a first powdered polymer, including a host cross-linking group bound to another of the first plurality of units via conversion of a carboxyl group of the other unit to a peptide bond; anda second quantity of a second powdered polymer, including a guest cross-linking group bound to one of the second plurality of the units, for binding with the host cross-linking group.2628-. (canceled)29. The kit of claim 24 , wherein ...

Variable-size hydrophobically-modified polymers

In various aspects, the invention provides compositions of variable-length hydrophobically-modified polymers. These variable-length hydrophobes decorated along the hydrophilic polymer backbone provide advanced properties and allow for precise control over the behavior of the resulting amphiphilic polymer, including in aqueous solution. Such control allows for enhanced functionality of the amphiphilic polymer relative to standard single-length hydrophobe grafting designs, including for hemostasis.

FORMULATIONS AND KITS FOR FORMING BIOADHESIVE MATRICES

A bioadhesive formulation, comprising gelatin, alginate and a coupling agent, capable of forming a bioadhesive matrix, which is characterized by rapid curing, optimal viscosity, high bonding strength, flexibility, biocompatibility and biodegradability, is disclosed. Further disclosed is such a bioadhesive formulation which further comprises a bioactive agent, and a drug-eluting bioadhesive matrix formed therefrom, the bioadhesive matrix being capable of delivering the bioactive agent to a bodily site. Methods utilizing the bioadhesive formulations and matrices in various biological and medical procedures are also disclosed. 1. A kit for preparing a bioadhesive formulation , comprising sub-formulation A and sub-formulation B , said sub-formulation A comprises gelatin and alginate dissolved in water and said sub-formulation B comprises a carbodiimide , whereas combining said sub-formulation A with said sub-formulation B affords the bioadhesive formulation , the bioadhesive formulation being for forming a bioadhesive matrix upon allowing a curing time to elapse , and wherein upon said combining:a concentration of said gelatin in the bioadhesive formulation ranges from 50 mg/ml to 400 mg/ml,a concentration of said alginate in the bioadhesive formulation ranges from 10 mg/ml to 60 mg/ml, anda concentration of said carbodiimide in the bioadhesive formulation ranges from 5 mg/ml to 50 mg/ml,such that prior to curing, the bioadhesive formulation is characterized by a room temperature viscosity that ranges from 1 Pa-sec to 50 Pa-sec, and such that said curing time ranges from 5 seconds to 30 minutes.2. The kit of claim 1 , wherein said carbodiimide in said sub-formulation B is dissolved in water.3. The kit of claim 1 , wherein said matrix is characterized by at least one of:a bonding strength of viable biological objects that ranges from 2,000 pascal to 60,000 pascal;a flexural strength at physiological conditions that ranges from 0.5 MPa to 200 MPa; anda biodegradability ...

WOUND TREATMENT

Use of a moulding composition comprising a polymer and a setting agent for wound debridement, wherein said use comprises adding water to said moulding composition to form a moulding fluid, applying said moulding fluid to a surface of a wound, allowing said moulding fluid to set in contact with said surface to form a solid covering on said surface, followed by removing said solid covering from the wound. The alginate composition adheres strongly to bacterial biofilms on the wound, whereby the biofilms are removed with the alginate composition. The moulding composition may be used in conjunction with a staining agent that undergoes a colour change in the presence of bacteria or bacterial polysaccharides to show the presence and removal of the biofilm. Also provided are methods of treating wounds using the compositions. 114-. (canceled)15. A kit comprising a moulding composition and instructions for performing a method for treating a wound; wherein the moulding composition comprises a water soluble polymer and a setting agent , the polymer comprises at least one polyanionic polysaccharide , and the setting agent comprises a divalent metal salt; and wherein the instructions compriseadding water to the moulding composition to form a moulding fluid, wherein the polymer and the setting agent are solids, and the moulding fluid comprises a solids to water ratio by weight of between 1:1 and 3:1;applying the moulding fluid to a surface of the wound;allowing the moulding fluid to set in contact with the surface to form a solid covering; andremoving the solid covering from the wound to debride the wound, wherein the removing is performed not more than six hours after the applying.16. The kit of claim 15 , wherein the kit further comprises a staining agent packaged separately from the water soluble polymer and the setting agent claim 15 , wherein the staining agent is adapted to undergo a colour change in the presence of bacteria or bacterial polysaccharides.17. The kit of claim ...

METHOD OF MANUFACTURING A TOY USING A MODEL FRAME IN LIQUID AND AN APPARATUS FOR PERFORMING A METHOD

A method of manufacturing a toy using a model frame in liquid includes: filling a water tank; dissolving calcium chloride, a powder component, into the water filled in the water tank; wherein the amount of calcium chloride is determined in anticipation of the degree of gelation by chemical action with sodium alginate, filling a liquid paint to the model frame; wherein the liquid paint is comprised water 96 wt. %, CNC 0.99 wt. %, sodium alginate 3 wt. %, luminous material 0.01 wt. % or water 91 wt. %, CNC 1 wt. %, sodium alginate 3 wt. %, shiny material 5 wt. % or water 96 wt. %, CNC 0.99 wt. %, sodium alginate 3 wt. %, color conversion material 0.01 wt. %; immersing the model frame filled with the liquid paint in the water tank; solidifying and shrinking the liquid paint filled in the model frame immersed in the water tank; and shaking the model frame. 1. A method of manufacturing a toy using a model frame in liquid comprising the steps of:filling a water tank with a certain amount of water so that a model frame can be completely immersed;dissolving calcium chloride, a powder component, into the water filled in the water tank;wherein the amount of calcium chloride is determined in anticipation of the degree of gelation by chemical action with sodium alginate,filling a liquid paint to the model frame;wherein the liquid paint is comprised water 96 wt. %, CNC 0.99 wt. %, sodium alginate 3 wt. %, luminous material 0.01 wt. % or water 91 wt. %, CNC 1 wt. %, sodium alginate 3 wt. %, shiny material 5 wt. % or water 96 wt. %, CNC 0.99 wt. %, sodium alginate 3 wt. %, color conversion material 0.01 wt. %,wherein the liquid paint is added with a predetermined dye and has a predetermined viscosity;immersing the model frame filled with the liquid paint in the water tank;solidifying and shrinking the liquid paint filled in the model frame immersed in the water tank; andshaking the model frame so that the solidified and contracted toy is separated from the model frame;wherein the ...

MUCOADHESIVE POLYMER COMPOSITIONS

Compositions of polymer matrices inclusive of hydrophobically modified and pH-responsive polymers which adhere to a biological tissue for use in delivery of active agents to mammalian subjects are provided. 1. A polymer matrix capable of adhering to a biological tissue , said polymer matrix comprising a hydrophobically modified polymer and a pH-responsive polymer.2. The polymer matrix of claim 1 , wherein the hydrophobically modified polymer is hydrophobically modified by attachment of one or more hydrophobic substituents to the polymer.3. The polymer matrix of claim 2 , wherein the hydrophobic substituent has an alkyl claim 2 , aryl claim 2 , or arylalkyl group.4. The polymer matrix of claim 1 , wherein the pH-responsive polymer is an alginate.5. The polymer matrix of claim 1 , wherein the the hydrophobically modified polymer is a chitosan or chitin.6. The polymer matrix of claim 5 , wherein a portion of the chitosan or chitin is hydrophobically modified.7. The polymer matrix of further comprising hydroxyethyl cellulose claim 1 , hydroxypropyl cellulose claim 1 , methyl cellulose claim 1 , hydroxypropyl methyl cellulose or hydroxyethyl methyl cellulose.8. The polymer matrix of further comprising an active agent.9. The polymer matrix of which exhibits enhanced mucoadhesivity as compared to a polymer matrix without a hydrophobically modified polymer.10. A polymer bead or sphere comprising the polymer matrix of .11. A composition for delivery of an active agent claim 1 , said composition comprising a polymer matrix comprising a hydrophobically modified polymer and a pH-responsive polymer and an active agent loaded on the polymer matrix.12. The composition of which exhibits enhanced mucoadhesivity as compared to a polymer matrix without a hydrophobically modified polymer.13. A method for producing a composition for delivery of an active agent claim 1 , said method comprising mixing or diffusing an active agent into the polymer matrix of .14. The method of wherein the ...

Photocontrolled dynamic covalent linkers for polymer networks

Reversibly crosslinkable polymeric networks, including reversibly crosslinkable hydrogel networks are provided. Also provided are methods of making the polymeric networks and methods of using the hydrogel networks in tissue engineering applications. The reversibly crosslinkable polymeric networks are composed of polymer chains that are covalently crosslinked by azobenzene boronic ester bonds that can be reversibly formed and broken by exposing the polymeric networks to different wavelengths of light.

HYDROGEL-BASED TRANSPARENT SOILS FOR PLANT GROWTH AND IN VIVO ROOT PHENOTYPING

The described invention is directed to hydrogel-based transparent soils that can provide heterogeneous, aeration, and porous condition for plant growth. The hydrogel beads are highly tailorable in size and porosity providing an environment that is closer to natural soil. Index-matching allows the beads to appear transparent, facilitating the use of imaging and microscopy of the plant root system in vivo. 1. A transparent soil for plant growth with the porosity and aeration characteristic of a natural soil comprising:a plurality of hydrogel beads comprising water in an amount of more than about 98% by weight; and one or more cross-linked polymers, wherein the cross-link comprises a divalent cation.2. The transparent soil of wherein said divalent cation is magnesium.3. The transparent soil of claim 1 , wherein said one or more polymers is present in an amount of from about 0.4% to about 1.2% by weight.4. The transparent soil of claim 1 , wherein said one or more polymers comprises a microbial exopolysaccharide with chains of two residues of D-glucose claim 1 , one L-rhamnose claim 1 , and one D-glucuronic acid.5Sphingomonas elodea.. The transparent soil of wherein said exopolysaccaride is produced by6. The transparent soil of wherein said exopolysaccaride is gellan.7. The transparent soil of wherein said one or more polymers comprises polymer comprises gellan gum and alginate.8. The transparent soil of claim 7 , wherein the ratio of gellan gum to alginate is about 4:1.9. The transparent soil of claim 1 , wherein the transparent soil is index-matched with an aqueous medium of interest.10. The transparent soil of claim 9 , wherein the aqueous medium of interest is a plant growth medium.11. The transparent soil of claim 1 , wherein said hydrogel beads have a size of from about 500 μm to about 5.5 mm.12. The transparent soil of claim 1 , wherein said hydrogel beads have an effective porosity of from about 0.05 to about 0.3.13. The transparent soil of claim 1 , wherein the ...

METHODS FOR REGENERATING A CARBON DIOXIDE CAPTURE ARTICLE

Methods for regenerating an article for capturing carbon dioxide (CO) from a gas stream include removing a COcapture sorbent from an adsorbent capture honeycomb. Removing the COcapture sorbent from the capture article may include contacting the adsorbent honeycomb and a volume of fluid, wherein the fluid removes the sorbent from the honeycomb, and the honeycomb binder is insoluble in the fluid. Restoring the article may include contacting the honeycomb with a regeneration fluid to deposit a COcapture sorbent on a surface of the honeycomb. 1. A method of removing a sorbent from an adsorbent honeycomb , the method comprising: wherein the honeycomb includes an extruded mixture of a powder, a binder, and a CO2 capture sorbent,', 'wherein the polar organic fluid removes the CO2 capture sorbent from the honeycomb, and', 'wherein the binder is insoluble in the polar organic fluid., 'contacting the adsorbent honeycomb with a volume of a polar organic fluid,'}2. The method of claim 1 , wherein the polar organic fluid is a liquid with a viscosity less than about 300 centipoise.3. The method of claim 1 , wherein the polar organic liquid is selected from the group consisting essentially of a glycol ether claim 1 , a polyether claim 1 , a ketone claim 1 , an ester claim 1 , an alcohol claim 1 , or a mixture thereof.4. The method of claim 1 , wherein the volume of the polar organic fluid is from about 5 to about 10 times a total volume of the honeycomb.5. The method of claim 1 , wherein the sorbent comprises an amine polymer.6. The method of claim 5 , wherein the amine polymer is selected from the group consisting of polyethyleneimine claim 5 , polyamidoamine claim 5 , and polyvinylamine.7. The method of claim 1 , wherein the binder comprises a solid organic compound.8. The method of claim 7 , wherein the solid organic compound is selected from the group consisting essentially of cellulosics claim 7 , methyl cellulose claim 7 , hydroxyethyl cellulose claim 7 , hydroxypropyl ...

SEMI-SOLID STATE NUCLEIC ACID MANIPULATION

The invention pertains to a method for isolating a nucleic acid, wherein the nucleic acid is stabilized in a hydrogel. The hydrogel can be dissolved to release the nucleic acid without breaking the molecule. A preferred hydrogel is alginate. The invention further concerns a method for sequencing the nucleic acid and a composition comprising the hydrogel and the nucleic acid. 1. A method for obtaining a hydrogel comprising a long manipulated nucleic acid , the method comprising:(a) combining a nucleic acid with an aqueous polymer solution;(b) gelling the polymer solution to form a hydrogel comprising the nucleic acid; and(c) manipulating the nucleic acid in the hydrogel,wherein the hydrogel can be dissolved at a temperature below 45° C.2. The method according to claim 1 , wherein the nucleic acid is provided in a carrier.3. The method according to claim 2 , wherein the carrier is at least one of an organelle and a cell.4. The method according to claim 3 , further comprising (c) lysing the organelle or to release the nucleic acid.5. The method according to claim 1 , wherein the polymers in the aqueous solution are at least one of:(i) ionic polymers, preferably anionic polymers having carboxylic pendant groups; and(ii) polysaccharides or derivatives thereof.6. The method according to claim 5 , wherein the polysaccharides or derivatives thereof comprise uronic acid.7. The method according to claim 5 , wherein the polysaccharides or the derivatives thereof are an alginate or a derivative thereof.8. The method according to claim 2 , wherein the carrier is a mitochondrion claim 2 , a chloroplast claim 2 , a nucleus claim 2 , a plant cell claim 2 , or a protoplast.9. The method according to claim 1 , wherein the nucleic acid is a DNA molecule.10. The method according to claim 1 , wherein the long manipulated nucleic acid is an isolated ultra-high molecular weight (uHMW) nucleic acid11. The method according to claim 1 , wherein the long manipulated nucleic acid is stabilized ...

Hydrogel patterning and transferring method of cells, and cell-based biosensor using same

Provided are a hydrogel-encapsulated cell patterning and transferring method comprising: preparing a substrate having a hydrogel-encapsulated cell patterning comprising a first cell and an alginate hydrogel; preparing an agarose hydrogel substrate comprising agarose hydrogel and any one of a second cell and a physiological active substance; and disposing the substrate having the hydrogel-encapsulated cell patterning on the agarose hydrogel substrate and transferring the cell patterning and a biosensor comprising: a first substrate having a hydrogel-encapsulated cell patterning comprising a first cell and an alginate hydrogel; and an agarose hydrogel second substrate comprising agarose hydrogel and any one of a second cell and a physiological active substance.

AIR TREATMENT AND LONG TERM FRAGRANCE RELEASE GEL

A method for producing a crosslinked gel. The method comprises steps of: (a) combining (i) water, (ii) alginic acid, alginates, or mixtures thereof, (iii) carboxymethylcellulose, (iv) a salt of calcium, magnesium or zinc, (v) a nonionic surfactant and (vi) fragrance to form a gel having a surface; and (b) contacting with the surface of said gel an additional aqueous solution of a salt of calcium, magnesium or zinc. 1. A method for producing a crosslinked gel; said method comprising steps of:(a) combining (i) water, (ii) alginic acid, alginates, or mixtures thereof,(iii) carboxymethylcellulose, (iv) a salt of calcium, magnesium or zinc, (v) a nonionic surfactant and (vi) fragrance to form a gel having a surface; and(b) contacting with the surface of said gel an additional aqueous solution of a salt of calcium, magnesium or zinc.2. The method of in which the gel comprises from 86 to 96 wt % water claim 1 , from 0.3 to 2.5 wt. % carboxymethylcellulose; from 0.3 to 2.5 wt. % alginic acid claim 1 , alginates claim 1 , or mixtures thereof; from 0.1 to 1 wt % of a salt of calcium claim 1 , magnesium or zinc claim 1 , or a combination thereof; from 0.2 to 2 wt % nonionic surfactant and from 1 to 6 wt % of one or more fragrances; and wherein said aqueous solution is added in an amount from 0.1 to 1 wt % and comprises from 2 to 20 wt % of a salt of calcium claim 1 , magnesium or zinc.3. The method of in which the salt is a calcium salt.4. The method of in which the carboxymethylcellulose has a molar degree of substitution MSof from 0.3 to 1.8.5. The method of in which a portion of the additional aqueous solution of a calcium salt is coated on the inside of a mold prior to addition of the gel to the mold and a portion of the additional aqueous solution of a calcium salt is applied to any portion of the gel surface not in contact with the mold.6. The method of in which the gel comprises from 90 to 95 wt % water claim 5 , from 0.6 to 1.5 wt. % carboxymethylcellulose; from 0.6 to ...

Decellularization and recellularization of whole organs

The present invention provides systems and methods for the decellularization and recellularization of tissue segments. In certain instances the invention comprises coating or sealing decellularized tissue segments with a cross-linked alginate hydrogel. The present invention also provides a decellularization kit, which may be used to generate decellularized tissue segments for high throughput studies. Also included are compositions and methods of tissue sealants comprising methacrylated alginate.

Dendritic Macroporous Hydrogels Prepared By Crystal Templating

The present invention includes a hydrogel and a method of making a porous hydrogel by preparing an aqueous mixture of an uncrosslinked polymer and a crystallizable molecule; casting the mixture into a vessel; allowing the cast mixture to dry to form an amorphous hydrogel film; seeding the cast mixture with a seed crystal of the crystallizable molecule; growing the crystallizable molecule into a crystal structure within the uncrosslinked polymer; crosslinking the polymer around the crystal structure under conditions in which the crystal structure within the crosslinked polymer is maintained; and dissolving the crystals within the crosslinked polymer to form the porous hydrogel. 1. (canceled)2. An apparatus comprising:a hydrogel film having first and second opposing ends;wherein the hydrogel film includes (a)(i) uncrosslinked hyaluronic acid, (a)(ii) crosslinked alginate, and (a)(iii) at least one of a protein and a biomineral;wherein (b)(i) the alginate is crosslinked with calcium, and (b)(ii) the alginate is crosslinked around the uncrosslinked hyaluronic acid.3. The apparatus of wherein the hydrogel film includes the biomineral.4. The apparatus of wherein the hydrogel film includes the protein.5. The apparatus of wherein the protein includes a cell adhesive protein.6. The apparatus of wherein the hydrogel film includes a drug.7. The apparatus of included in a kit claim 4 , the kit comprising a calcium chelator.8. The apparatus of claim 4 , wherein the hydrogel film consists essentially of the uncrosslinked hyaluronic acid and the crosslinked alginate.9. The apparatus of wherein the hydrogel film includes chitosan.10. The apparatus of wherein the hydrogel film includes urea.11. The apparatus of wherein the hydrogel film includes at least one crystal.121. The apparatus of wherein the at least one crystal is (a) dendritically branched claim 11 , and (b) at least micron in diameter.13. The apparatus of wherein the at least one crystal comprises cyclodextrin.14. An ...

PHOTOCONTROLLED DYNAMIC COVALENT LINKERS FOR POLYMER NETWORKS

Reversibly crosslinkable polymeric networks, including reversibly crosslinkable hydrogel networks are provided. Also provided are methods of making the polymeric networks and methods of using the hydrogel networks in tissue engineering applications. The reversibly crosslinkable polymeric networks are composed of polymer chains that are covalently crosslinked by azobenzene boronic ester bonds that can be reversibly formed and broken by exposing the polymeric networks to different wavelengths of light. 1. A reversibly crosslinkable composition comprising:a first molecule comprising at least two terminal azobenzene boronic acid groups; anda second molecule comprising at least two terminal diol groups, wherein at least one of the first and second molecules is a polymer, and further wherein, if the first molecule has only two terminal azobenzene boronic acid groups, then the second molecule comprises at least three terminal diol groups, and if the second molecule has only two terminal diol groups, the first molecule has at least three terminal azobenzene boronic acid groups;wherein the first molecule is characterized in that its azobenzene groups undergo a reversible E to Z isomerization upon irradiation with ultraviolet light, visible light, or infrared light, and its boronic acid groups react with the terminal diol groups of the second polymer to form a polymer network comprising covalent azobenzene boronic ester bonds.2. The composition of claim 1 , wherein one or both of the first molecule and the second molecule comprise polysaccharide chains.3. The composition of claim 2 , wherein the polysaccharide chains comprise hyaluronic acid chains.4. The composition of claim 1 , wherein one or both of the first molecule and the second molecule comprise poly(ethylene glycol) chains.5. The composition of claim 1 , wherein one or both of the first molecule and the second molecule comprise decellularized extracellular matrix.6. The composition of claim 1 , wherein one or both of ...

SULFATED ALGINATE HYDROGELS FOR CELL CULTURE AND THERAPY

The present invention relates to a method for providing an embedded mammalian cell, comprising the steps of providing an alginate sulfate in aqueous solution; reacting the alginate sulfate to form a hydrogel in a gelation step, providing a precursor cell, and embedding the precursor cell in the sulfated alginate hydrogel in an embedding step, thus yielding an sulfated alginate hydrogel embedded cell. The invention further relates to sulfated alginate hydrogels, and cellular grafts comprising a mammalian cell embedded in sulfated alginate hydrogel. 1. A sulfated alginate hydrogel , comprising sulfated alginate having a degree of sulfation between 0.1 and 1 per monomer.2. The sulfated alginate hydrogel of claim 1 , wherein the sulfated alginate has a degree of sulfation between 0.5 and 0.9 per monomer.3. The sulfated alginate hydrogel of claim 1 , wherein said sulfated alginate hydrogel has a content of sulfated alginate of 0.1 to 5% (m/m).4. The sulfated alginate hydrogel of claim 1 , wherein said sulfated alginate hydrogel is characterized by a viscosity of 180 to 220 Pa/s.5. The sulfated alginate hydrogel of claim 4 , wherein said sulfated alginate hydrogel is characterized by a viscosity of about 200 Pa/s.6. The sulfated alginate hydrogel of claim 1 , wherein said sulfated alginate is further modified by aldehyde moieties claim 1 , carboxyl moieties claim 1 , amino moieties claim 1 , vinyl sulfone moieties claim 1 , thiol moieties claim 1 , or saturated or unsaturated ester or ether groups.7. The sulfated alginate hydrogel of claim 1 , wherein said sulfated alginate is further modified by acrylate or methacrylate ester groups.8. A method for providing a sulfated alginate hydrogel embedded mammalian cell claim 1 , comprising the steps of:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'providing the sulfated alginate hydrogel of ,'}providing a precursor cell,embedding said precursor cell in said sulfated alginate hydrogel in an embedding step, thus yielding a ...

NATURAL POLYMER-BASED TISSUE ADHESIVE WITH HEALING-PROMOTING PROPERTIES

A tissue adhesive for contacting a tissue site, the tissue adhesive comprising: a mixture of natural polymers; and an activating agent enhancing the adhesive properties of the mixture of natural polymers. And a tissue adhesive for contacting a tissue site, the tissue adhesive comprising: a mixture of natural polymers; and an aqueous solution of a water soluble starch or a water soluble starch derivative which forms a gel with the addition of the mixture of natural polymers. 1. A tissue adhesive for contacting a tissue site , the tissue adhesive comprising:a mixture of natural polymers; andan activating agent enhancing the adhesive properties of the mixture of natural polymers.219.-. (canceled)20. A method comprising: a mixture of natural polymers; and', 'an activating agent enhancing the adhesive properties of the mixture of natural polymers., 'positioning a tissue adhesive on a tissue site, wherein the tissue adhesive comprises2143.-. (canceled)44. A tissue adhesive for contacting a tissue site , the tissue adhesive comprising:a mixture of natural polymers; andan aqueous solution of a water soluble starch or a water soluble starch derivative which forms a gel with the addition of the mixture of natural polymers.4561.-. (canceled)62. A method comprising: a mixture of natural polymers; and', 'an aqueous solution of a water soluble starch or a water soluble starch derivative which forms a gel with the addition of the mixture of natural polymers., 'positioning a tissue adhesive on a tissue site, wherein the tissue adhesive comprises63. A method according to wherein the tissue site comprises at least one from the group consisting of a surgical site created during a tonsillectomy surgery claim 62 , a surgical site created during an adenoidal surgery claim 62 , a burn site claim 62 , a skin donor site claim 62 , a skin graft site and a joinder site between two pieces of tissue.6466.-. (canceled)67. A method according to wherein the natural polymers are selected from the ...

PREPARATION METHOD OF MINIATURE INTELLIGENT CALCIUM ALGINATE HYDROGEL END OPERATOR

A preparation method of a miniature intelligent calcium alginate hydrogel end operator based on different microelectrodes is introduced. The method includes an electrodeposition step of depositing a deposition solution under the action of a non-uniform magnetic field to form an anode surface; a processing step of transferring obtained hydrogel microstructures to a calcium chloride solution, making the hydrogel microstructure self-wind sufficiently; and a pickup step of collecting a self-winding single-layer film alginate microstructure in a culture dish, and placing it in specific environment for preservation. The preparation method can provide a degradable and convenient micro-operator, which could be locally prepared into different function components. 1. A preparation method of a degradable and self-winding miniature intelligent calcium alginate hydrogel end operator , comprising: electrodeposition , processing and pickup.2. The preparation method of a degradable and self-winding miniature intelligent calcium alginate hydrogel end operator according to claim 1 , characterized in that: the electrodeposition step further comprises:a1: coating a photoresist on an FTO glass by a spin coater, and forming a concave pattern with a specific shape on the FTO glass as an anode;a2: filling a deposition solution between two electrodes and maintaining the deposition solution by insulating spacers with a height of 1 mm;a3: applying direct voltage to the electrodes for 1 to 5 seconds; anda4: washing the anode in an HEPES buffer solution for 5 minutes until all hydrogel microstructures are separated from the FTO glass.3. The preparation method of a degradable and self-winding miniature intelligent calcium alginate hydrogel end operator according to claim 1 , characterized in that the electrodeposition step further comprises:a1: coating the photoresist on the FTO glass by the spin coater, and forming the concave pattern with the specific shape on the FTO glass as the anode;a2: ...

PAPER STRENGTH IMPROVING ADDITIVES, THEIR MANUFACTURE AND USE IN PAPER MAKING

The present invention relates to a polymer composition comprising an anionic polymer composite having a synthesized polymer portion and a polysaccharide portion, obtainable by polymerizing vinyl monomers in the presence of the polysaccharide. The present invention further relates to a strength system and methods of production and use in providing a paper product. 1. A polymer composition comprising an anionic polymer composite having a synthesized polymer portion and an anionic polysaccharide portion , obtainable by polymerizing vinyl monomers in the presence of an anionic polysaccharide.2. The polymer composition according to claim 1 , having a solids content originating from the anionic polymer composite of about 1-50 wt % claim 1 , preferably about 5-50 wt % claim 1 , more preferably about 10-30 wt % claim 1 , based on the total weight of the polymer composition.3. The polymer composition according to claim 1 , wherein the anionic polymer composite has a Brookfield viscosity of about 3-1200 mPas claim 1 , preferably 7-300 mPas claim 1 , more preferably 12-150 mPas claim 1 , when measured from an aqueous solution of the polymer composition having solids content of 2 weight-% using a Brookfield LVT viscometer with a #2 spindle at 60 rpm at pH 7 claim 1 , 23° C.4. The polymer composition according to any one of claim 1 , wherein vinyl monomers providing nonionic units to the synthesized polymer portion of the composite are selected from the group consisting of acrylamide-based monomers claim 1 , acrylate-based monomers claim 1 , N-vinylcarbamides claim 1 , styrene claim 1 , acrylonitrile claim 1 , vinyl acetate claim 1 , N-vinylpyrrolidone claim 1 , N-vinyl-2-caprolactam claim 1 , maleic anhydride claim 1 , vinylethers claim 1 , and any combinations thereof; preferably acrylamide-based monomers.5. The polymer composition according to any one of claim 1 , wherein vinyl monomers providing anionic units to the synthesized polymer portion of the composite are selected ...

PRINTABLE MORPHOGENETIC PHASE-SPECIFIC CHITOSAN-CALCIUM-POLYPHOSPHATE SCAFFOLD FOR BONE REPAIR

This invention concerns a formula for the synthesis of a printable hybrid material, formed of carboxymethyl chitosan (CMC) and polyphosphate (polyP). Both polymers are linked together by calcium ions. The inventive CMC-polyP material, in combination with alginate, is biocompatible, biodegradable and useful for three-dimensional (3D) printing and 3D cell printing (bioprinting). The CMC-polyP scaffold, hardened by exposure to calcium ions, is morphogenetically active and can be used in bone N tissue engineering, as a bio mimetic 3-phase scaffold that mimics and induces essential phases in bone repair, including blood clot formation and platelet degranulation (release of growth factors and cytokines) (Phase 1: initiation phase), calcium carbonate bioseed formation (Phase 2: nucleation) and expression/activation of bone alkaline phosphatase (Phase 3: hydroxyapatite-biomineral. 1. A method for the preparation of a scaffold for tissue engineering and repair , comprising the steps of:i) combining carboxymethyl chitosan, polyphosphate, and alginate; to form a hydrogel;ii) three-dimensional (3D) printing of the resulting hydrogel; andiii) hardening, by exposure to calcium ions, of the material after printing.2. The method according to claim 1 , wherein said carboxymethyl chitosan has been formed by carboxymethylation of the amino groups of chitosan (N-carboxymethyl chitosan) or the hydroxy groups of chitosan (O-carboxymethyl chitosan) claim 1 , or both (N claim 1 ,O-carboxymethyl chitosan).3. The method according to claim 1 , wherein non-carboxymethylated (free) amino groups or hydroxy groups claim 1 , or both claim 1 , of said carboxymethyl chitosan are acetylated or partially acetylated.4. The method according to claim 1 , wherein said polyphosphate and the alginate are present as a sodium salt.5. The method according to claim 1 , wherein the average chain length of the polyphosphate is between 10 and 100 phosphate units.6. The method according to claim 5 , wherein the ...

IN-SITU CROSS-LINKABLE POLYMERIC COMPOSITIONS AND METHODS THEREOF

A biocompatible polymeric composition for cross-linking in-situ in a wound is disclosed comprising 1) one or more polyanionic polymers such as alginates or hyaluronates, able to be cross-linked the surface of the wound and 2) one or more polycationic polymers such as chitosan or DEAE-Dextran, that assists in the solidification process as well as speeds up hemostasis without the need for applying pressure. The biocompatible polymeric composition may further comprise a cross-linking agent such as aqueous calcium chloride. The invention encompasses an initial polymeric composition, the solidified matrix cross-linked and integrated at the wound site, including the methods of using, applying, and cross-linking the composition. 1. A biocompatible polymeric composition comprising:a. about 0.1% to about 95% by weight of one or more than one polyanionic polymer;b. about 0.1% to about 90% by weight of one or more than one polycationic polymer; andc. 0.1% to 99.8% by weight water.2. A biocompatible polymeric composition of wherein the one or more than one polyanionic polymer comprises at least one cross-linkable polyanionic polymer.3. A biocompatible polymeric composition of wherein the one or more than one polyanionic polymer further comprises at least one non-cross-linkable polyanionic polymer.4. A biocompatible polymeric composition of claim 3 , wherein at least one cross-linkable polyanionic polymer is selected from the group consisting of: a polystyrene sulfonate claim 3 , a polyacrylate claim 3 , a polymethacrylate claim 3 , a polyvinyl sulphate claim 3 , a polyphosphate claim 3 , Iota carrageenan claim 3 , Kappa carrageenan claim 3 , gellan gum claim 3 , carboxyl methyl cellulose claim 3 , carboxyl methyl agarose claim 3 , carboxyl methyl dextran claim 3 , carboxyl methyl chitin claim 3 , carboxyl methyl chitosan claim 3 , a polymer modified with a carboxyl methyl group claim 3 , an alginate claim 3 , a polymer containing a plurality of carboxylate groups claim 3 , and ...

SCAFFOLD SYSTEM FOR TISSUE REPAIR

A device for treating a damaged tissue includes an expandable scaffold positionable in a portion of a luminal tissue structure of a mammal; and maintained via stent technology, wherein the scaffold is comprised of electrospun fibers composed of a biodegradable compound. The scaffold serves as a temporary template that allows the tissue to be rebuilt. 1. A vascular tissue repair device , comprising:a generally tubular intraluminal scaffold having a luminal surface and an abluminal surface and being composed of nonwoven fibers made of a biodegradable and/or bioresorbable material, the luminal surface being comprised of substantially curvilinear nonwoven fibers and the abluminal surface comprising substantially linear fibers and the abluminal surface being adapted to face and be in apposition to a luminal wall of the vascular tissue;wherein the generally tubular intraluminal scaffold has an average porosity capable of cellular permeability.231. The vascular tissue repair device according to claim , wherein the nonwoven fibers are made of poly(α-hydroxy esters).331. The vascular tissue repair device according to claim , wherein the nonwoven fibers are made of polycaprolactone.431. The vascular tissue repair device according to claim , wherein the generally tubular intraluminal scaffold further comprises elastin , collagen , DNA , RNA , glucosaminoglycans , polyhydroxyalkanoates or mixtures thereof.531. The vascular tissue repair device according to claim , further comprising a stent.635. The vascular tissue repair device according to claim , wherein the stent and the generally tubular intraluminal scaffold are diametrically expandable into apposition with the luminal wall of the vascular tissue.731. The vascular tissue repair device according to claim , wherein the nonwoven fibers are electrospun fibers.831. The vascular tissue repair device according to claim , wherein the nonwoven fibers are electrospun fibers and the stent is incorporated into the electrospun fibers. ...

Preparation and/or Formulation of Proteins Cross-Linked with Polysaccharides

Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.

High density fibrous polymers suitable for implant

This invention includes malleable, biodegradable, fibrous compositions for application to a tissue site in order to promote or facilitate new tissue growth. One aspect of this invention is a fibrous component that provides unique mechanical and physical properties. The invention may be created by providing a vessel containing a slurry, said slurry comprising a plurality of natural or synthetic polymer fibers and at least one suspension fluid, wherein the polymer fibers are substantially evenly dispersed and randomly oriented throughout the volume of the suspension fluid; applying a force, e.g., centrifugal, to said vessel containing said slurry, whereupon said force serves to cause said polymer fibers to migrate through the suspension fluid and amass at a furthest extent of the vessel, forming a polymer material, with said polymer material comprising polymer fibers of sufficient length and sufficiently viscous, interlaced, or interlocked to retard dissociation of said polymer fibers.

DRY MATRIX FOR EMBEDDING VIABLE ESCHERICHIA COLI, METHOD OF MAKING SAME AND USE THEREOF

There is provided viable () embedded in a matrix, wherein said matrix has a water activity (a)≤0.3, and wherein said matrix comprises a hydrocolloid-forming polysaccharide, a second polysaccharide which is different from the first polysaccharide, and a disaccharide which includes sucrose, trehalose, or a combination thereof. There is also provided methods of making same and use thereof. 127-. (canceled)28Escherichia coliE. coliE. coli. A method for protecting viability of () during a drying process , the method comprising: forming particles comprising the embedded in alginate , and a preservation solution including maltodextrin or dextran , and sucrose or trehalose , wherein the drying process includes drying said particles to obtain a water activity (a) of ≤0.3.29. The method of claim 28 , wherein said forming particles comprises:{'i': 'E. coli', 'mixing said with the alginate to form a mixture;'}forming the particles from the mixture; andcontacting the particles with the preservation solution.30. The method of claim 28 , wherein said preservation solution includes a ratio of the sucrose or trehalose/maltodextrin or dextran of less than 10 claim 28 , wherein the ratio is wt. %/wt. %.31. The method of claim 30 , wherein the ratio is of less than 5.32. The method of claim 30 , wherein the ratio is of about 1.33. The method of claim 28 , wherein said particles further comprise a salt of L-glutamic acid.34. The method of claim 33 , wherein said salt is sodium salt of L-glutamic acid.35Escherichia coliE. coliE. coli. A method for increasing viability of () in a dry state claim 33 , the method comprising: forming particles comprising the embedded in alginate claim 33 , and a preservation solution including maltodextrin or dextran claim 33 , and sucrose or trehalose claim 33 , and drying said particles to obtain a water activity (a) of ≤0.3.36. The method of claim 35 , wherein said drying is performed to obtain 0.04≤a≤0.3.37. The method of claim 35 , wherein said forming ...

Dendritic Macroporous Hydrogels Prepared By Crystal Templating

The present invention includes a hydrogel and a method of making a porous hydrogel by preparing an aqueous mixture of an uncrosslinked polymer and a crystallizable molecule; casting the mixture into a vessel; allowing the cast mixture to dry to form an amorphous hydrogel film; seeding the cast mixture with a seed crystal of the crystallizable molecule; growing the crystallizable molecule into a crystal structure within the uncrosslinked polymer; crosslinking the polymer around the crystal structure under conditions in which the crystal structure within the crosslinked polymer is maintained; and dissolving the crystals within the crosslinked polymer to form the porous hydrogel. 1. A hydrogel that comprises molecular pores, the hydrogel comprising: one or more crosslinked polymers formed about a plurality of pre-formed molecular crystals, wherein the crystals are formed while the polymer is in an uncrosslinked form and the molecular crystals form a porous structure within the polymers during the crosslinking of the polymers. This application is a continuation of U.S. patent application Ser. No. 16/597,106, filed Oct. 9, 2019, which is a continuation of U.S. patent application Ser. No. 15/890,719, filed Feb. 7, 2018, now U.S. Pat. No. 10,442,911, issued Oct. 15, 2019, which is a continuation of U.S. patent application Ser. No. 15/135,978, filed Apr. 22, 2016, now U.S. Pat. No. 9,896,561, issued Feb. 20, 2018, which is a continuation of U.S. patent application Ser. No. 14/277,170, filed May 14, 2014, now U.S. Pat. No. 9,320,827, issued Apr. 26, 2016, which is a continuation of U.S. patent application Ser. No. 13/909,707, filed Jun. 4, 2013, now U.S. Pat. No. 8,728,499, issued May 20, 2014, which is a continuation of U.S. patent application Ser. No. 12/919,667, filed Aug. 26, 2010, now U.S. Pat. No. 8,668,863, issued Mar. 11, 2014, which claims priority to Patent Cooperation Treaty Application Serial No. PCT/US2009/035257, filed Feb. 26, 2009, which claims priority to U. ...

AGENT FOR BIOLOGICAL DAMAGE REPAIR OR HEMOSTASIS AND THE METHOD THEREOF

The purpose of the present invention is to provide a light control agent and explore its application, and is expected to improve the tissue binding force and convenience of the existing biological glue material by providing a new reagent or material for biological damage or homeostasis. In one of embodiment, this invention provides an agent for repairing biological damage or homeostasis, wherein the agent comprises a natural biological macromolecule modified by the photo-responsive cross-linking group. 1. An agent for repairing biological damage or homeostasis , wherein the agent comprises a natural biological macromolecule modified by the photo-responsive cross-linking group; a natural biological macromolecule modified with photo triggered o-nitrobenzyl groups; a photo initiator and/or deionized water.2. The reagent of claim 1 , wherein the final concentration of the natural biological macromolecule modified by the light-responsive cross-linking group is 0.1 to 10% based on the mass of the deionized water.3. The reagent of claim 2 , wherein the final concentration of natural biological macromolecules modified by the photo triggered o-nitrobenzyl group is 0.1-10% based on the mass of the deionized water.4. The reagent of claim 3 , wherein the final mass concentration of the photo initiator is from 0.001 to 1% based on the mass of the deionized water.5. The reagent of claim 2 , wherein the light-responsive cross-linking group-modified natural biological macromolecule has a graft substitution rate of 10-90% of the photo-responsive cross-linking group.6. The reagent of claim 2 , wherein the light-responsive cross-linking group is methacrylamide or methacrylic anhydride.7. The reagent of claim 3 , wherein the o-nitrobenzyl type photo initiator in the o-nitrobenzyl type photo initiator-modified natural bio-macromolecule has a graft substitution rate of 1-100%.8. The reagent of claim 2 , wherein the photo-reactive cross-linking group in the photo-reactive cross-linking ...

Method and apparatus for adhesive bonding in an aqueous medium

The disclosure is directed to an adhesive material which can be applied underwater comprising hydrophilic adhesive molecules. In other embodiments, the adhesive material may also include hydrophilic polymers and/or an oxidizing agent.

Biobased Super-Absorbing Polymers

The present invention is in the field of extraction a product for liquid absorption comprising a low-density biopolymer, such as obtainable from a granular sludge, in particular alginate or bacterial alginate, wherein the biobased polymer acts as a super-absorbing material, and a method of obtaining said product. 123-. (canceled)24. A product for liquid absorption comprising:a super-absorbing material of biobased polymer, wherein the biobased polymer is produced by a microorganism selected from bacteria, algae and fungi, comprising 20-99.8 wt. % low density polymer material, with a density <0.5 gr/cm3,wherein the super-absorbing biobased polymer material is a non-woven material, and/or wherein the super-absorbing biobased polymer material comprises fibres, and/or wherein the super-absorbing biobased polymer material comprises a powder with particle sizes >0.1 mm,0-80 wt. % fillers,0-10 wt. % cross-linking agent,0-30 wt. % water-soluble polymer,0-2 wt. % buffer,0-2 wt. % additive,0-5 wt. % lipids, andthe remainder being water, wherein all percentages are relative to a total weight of the super-absorbing material.25. The product according to claim 24 , wherein the product is selected from a diaper claim 24 , an incontinence product claim 24 , concrete claim 24 , a personal hygiene product claim 24 , a soil-improver claim 24 , a water retainer claim 24 , a wound dressing claim 24 , a liquid absorbent claim 24 , a thermal insulator claim 24 , a thermal clothing layer claim 24 , a thermal insulating panel claim 24 , a protective sheet or laminate claim 24 , a filter claim 24 , and an absorbent pan component.26. The product according to claim 24 , wherein the biobased polymer is produced by a microorganism claim 24 , selected from the order Pseudomonadaceae claim 24 , the order Planctomycetales claim 24 , and algae claim 24 , and the biobased polymer is alginate.27. The product according to claim 24 , wherein the super-absorbing biobased polymer is immobilized in the ...

CROSS-LINKED BINDER COMPOSITION FOR LITHIUM ION BATTERIES AND METHODS FOR PRODUCING THE SAME

The presently disclosed and/or claimed inventive concept(s) relates to a binder composition comprising a cross-linked polymer system. The cross-linked polymer system comprises an ionizable water soluble polymer cross-linked with a component using an esterification catalyst and/or an epoxy resin with two or more epoxide groups. The presently disclosed and/or claimed inventive concept(s) also relates generally to the compositions and methods of making electrodes, in particular but without limitation, anodes, with a binder composition comprising an ionizable water soluble polymer cross-linked with a component. 165-. (canceled)66. A binder composition for a lithium ion battery electrode comprising a cross-linked polymer system , wherein the cross-linked polymer system comprises (i) an ionizable water soluble polymer at least partially cross-linked with a component , and (ii) at least one of (a) an esterification catalyst and (b) an epoxy resin comprising at least two epoxide groups , and wherein the cross-linked polymer system is insoluble in water.67. The binder composition of claim 66 , wherein the ionizable water soluble polymer comprises at least one of xanthan gum claim 66 , alginate claim 66 , and an anionically modified polysaccharide selected from the group consisting of carboxyalkyl cellulose claim 66 , carboxyalkyl hydroxyalkyl cellulose claim 66 , and combinations thereof claim 66 , and wherein the ionizable water soluble polymer comprises at least one hydroxyl group.68. The binder composition of claim 67 , wherein the ionizable water soluble polymer comprises at least one of lithiated xanthan gum claim 67 , lithiated alginate claim 67 , and a lithiated anionically modified polysaccharide selected from the group consisting of lithiated carboxyalkyl cellulose claim 67 , lithiated carboxyalkyl hydroxyalkyl cellulose claim 67 , and combinations thereof.69. The binder composition of claim 66 , wherein the component is a synthetic polymer comprising at least one ...

Scaffold for cardiac patch

A biocompatible and biodegradable medical device patch actuating primarily as soft tissue structural reinforcement. The device has a layered architecture, where the primary serves as suturing layer and mechanical support to a thick porous scaffold which can be coated with a mimic-like extra cellular matrix (ECM). The device can be provided to the end user under the format of independent layers that can be cut and assembled to the specific need to the end user and patient. The layers are assembled without the need of any adhesive. Totally haemocompatible and of behavior superior to polytetrafluoroethylene used for any soft tissue repaired, the field of this invention is demonstrated for cardiovascular therapy but should not be limited to it. It is of practical relevance of vein, tendon and hernias and dermal treatments.

Alginate Coating for Sett Treatment

Disclosed are methods of treating setts comprising (a) applying a coating of an alginate optionally containing one or more crop protection agents and/or one or more nutrients, and (b) crosslinking the alginate with a divalent metal ion. Also disclosed are compositions used in the disclosed methods of treating setts.

Injectable Cryogel Vaccine Devices and Methods of Use Thereof

The invention provides polymer compositions for cell and drug delivery. 1. An injectable cancer vaccine device comprising a cell-adhesive cryogel composition comprising open interconnected macropores ,wherein said cryogel composition comprises at least 75% pores,wherein said cryogel composition is characterized by shape memory following deformation by compression through a needle,wherein said cryogel composition comprises a crosslinked gelatin polymer or a crosslinked alginate polymer, andwherein said cryogel composition comprises a cancer antigen.2. The device of claim 1 , wherein said gelatin or alginate is acrylated or methacrylated.3. The device of claim 1 , wherein the device recruits a cell into the cryogel composition upon injection into a subject.4. The device of claim 3 , wherein the cryogel composition is degraded by the recruited cell.5. The device of claim 1 , wherein the cryogel composition is formed by cryopolymerization of methacrylated gelatin or methacrylated alginate.6. The device of claim 5 , wherein the cryogel comprises a methacrylated gelatin macromonomer concentration of 0.5% to 1.4% (w/v).7. The device of claim 1 , wherein said cryogel composition comprises a living attenuated cancer cell.8. The device of claim 1 , wherein said composition comprises a biomolecule in one or more of said open interconnected pores.9. The device of claim 8 , wherein said biomolecule comprises a small molecule claim 8 , nucleic acid claim 8 , or protein.10. The device of claim 9 , wherein said protein comprises GM-CSF.11. The device of claim 9 , wherein said nucleic acid comprises a CpG nucleic acid oligonucleotide (CpG-ODN).12. The device of claim 1 , wherein the cryogel composition is between 100 μmto 100 mmin size.13. A method for eliciting an anti-cancer immune response claim 1 , comprising administering to a subject the device of .14. The method of claim 13 , wherein the device is injected into the subject once to 5 times in the lifetime of the subject.15. ...

ALGINATE MONOMER STRUCTURE WITH METAL CRYSTALLITE EMBEDDED, ALGINATE SALT STRUCTURE WITH METAL CRYSTALLITE EMBEDDED AND METHOD OF PRODUCING ALGINATE HYDROGEL WITH METAL CRYSTALLITE INCORPORATED

An alginate monomer structure with metal crystallite embedded includes a first alginate monomer and at least a first metal crystallite. The first alginate monomer is composed of a first uronate molecule and a second uronate molecule, which are linked linearly to each other. A first carbonyl group is formed on a second carbon atom (C2) of the main ring in the first uronate molecule, a carboxyl group is presented on a sixth carbon atom (C6) of the main ring in the second uronate molecule, and a first intramonomer glycosidic linkage is presented between a first carbon atom (C1) of the main ring in the first uronate molecule and a fourth carbon atom (C4) of the main ring in the second uronate molecule. The first metal crystallite is associated between the first uronate molecule and the second uronate molecule. 1. An alginate monomer structure with metal crystallite embedded , comprising:a first alginate monomer composed of a first uronate molecule and a second uronate molecule linked linear to each other, wherein a first carbonyl group is formed on a second carbon atom (C2) of a main ring in the first uronate molecule; and a first intramonomer glycosidic linkage is presented between a first carbon atom (C1) in the first uronate molecule and a fourth carbon atom (C4) in the second uronate molecule; andat least a first metal crystallite associated between the first uronate molecule and the second uronate molecule.2. The alginate monomer structure with metal crystallite embedded according to claim 1 , wherein a first carboxyl group is presented on the second uronate molecule claim 1 , and the at least a first metal crystallite is associated between the first carbonyl group and the first carboxyl group.3. The alginate monomer structure with metal crystallite embedded according to claim 1 , wherein the first uronate molecule and the second uronate molecule are selected from α-L-guluronate or β-D-mannuronate claim 1 , respectively.4. The alginate monomer structure with metal ...

IN-SITU CROSS-LINKABLE POLYMERIC COMPOSITIONS AND METHODS THEREOF

A biocompatible polymeric composition for cross-linking in-situ in a wound is disclosed comprising 1) one or more polyanionic polymers such as alginates or hyaluronates, able to be cross-linked the surface of the wound and 2) one or more polycationic polymers such as chitosan or DEAE-Dextran, that assists in the solidification process as well as speeds up hemostasis without the need for applying pressure. The biocompatible polymeric composition may further comprise a cross-linking agent such as aqueous calcium chloride. The invention encompasses an initial polymeric composition, the solidified matrix cross-linked and integrated at the wound site, including the methods of using, applying, and cross-linking the composition. 121-. (canceled)22. A biocompatible polymeric composition comprising:a. 0.1% to 5% by weight of sodium alginate;b. 2% to 25% by weigh of chitosan; andc. the balance of the composition is water.23. The biocompatible polymeric composition of claim 22 , wherein the composition comprises 2% to 5% by weight of sodium alginate.24. The biocompatible polymeric composition of claim 22 , wherein the chitosan is chitosan chloride.25. The biocompatible polymeric composition of claim 22 , wherein the composition comprises 73% to 93% by weight of water.26. The biocompatible polymeric composition of claim 22 , wherein the composition forms a gelatinous matrix.27. A container comprising the biocompatible composition of .28. The container of claim 27 , wherein the container is a packet claim 27 , sachet claim 27 , tube claim 27 , tub claim 27 , pump claim 27 , syringe claim 27 , bottle claim 27 , bag or aerosol-based spray can.29. The container of claim 26 , wherein the container is a syringe.30. A kit comprising the biocompatible composition of . This application claims the benefit of provisional patent application Ser. No. 61/559,110, filed 13 Nov. 2011, the entire disclosure of which is incorporated herein by reference.The present invention relates generally to ...

DRY MATRIX FOR EMBEDDING VIABLE ESCHERICHIA COLI, METHOD OF MAKING SAME AND USE THEREOF

There is provided viable () embedded in a matrix, wherein said matrix has a water activity (a)≤0.3, and wherein said matrix comprises a hydrocolloid-forming polysaccharide, a second polysaccharide which is different from the first polysaccharide, and a disaccharide which includes sucrose, trehalose, or a combination thereof. There is also provided methods of making same and use thereof. 1. A particle comprising:{'i': Escherichia coli', 'E. coli', 'E. coli, 'a first composition including a first polysaccharide in the form of a matrix and a viable (), wherein the viable is embedded in the matrix, and wherein the first polysaccharide is a hydrocolloid-forming polysaccharide, and'}a second composition free of the first polysaccharide, the second composition including a second polysaccharide and a disaccharide,{'sub': 'w', 'wherein the particle has a water activity (a)≤0.3.'}2. The particle of claim 1 , wherein the first polysaccharide includes alginate.3. The particle of claim 1 , wherein 0.04≤a≤0.3.4. The particle of claim 1 , wherein said second composition comprises a ratio disaccharide/second polysaccharide of less than 10 claim 1 , wherein the ratio is wt. %/wt. %.5. The particle of claim 4 , wherein the ratio is of less than 5.6. The particle of claim 4 , wherein the ratio is of about 1.7. The particle of claim 1 , wherein said second composition further comprises a salt of L-glutamic acid.8. The particle of claim 7 , wherein said salt is sodium salt of L-glutamic acid.9. The particle of claim 1 , wherein said second polysaccharide includes maltodextrin.10. The particle of claim 1 , wherein said second polysaccharide includes dextran.11E. coliE. coli.. The particle of claim 1 , wherein said includes a non-pathogenic12E. coli. The particle of claim 1 , wherein said non-pathogenic includes the strain deposited at the International Depository Authority of Canada (IDAC) on Jan. 21 claim 1 , 2005 claim 1 , under accession number IDAC 210105-01.13E. coli. The particle ...

Hydrogel Membrane for Adhesion Prevention

A biocompatible membrane comprised of alginate and hyaluronate. The membrane may be used to prevent unwanted scarring after surgery. The tissue adherence and the rate of bioresorption of the membrane may be modified through an external stimulus comprising a sequestering agent and a viscosity modifier. 1uncrosslinked hyaluronic acid and crosslinked alginate both included in a hydrogel film; anda calcium chelator;wherein (a) the alginate is crosslinked with calcium, (b) the hydrogel film is flat and includes a width, a length, and a thickness that is less than the width and the length, and (c) the hydrogel film is configured so bioresorbability of the hydrogel film increases in response to applying the calcium chelator to the hydrogel film.. A kit comprising: This application is a continuation of U.S. patent application Ser. No. 14/758,873, filed Jul. 1, 2015, which is a §371 National Stage Entry of International Application No. PCT/US2013/074388 filed on Dec. 11, 2013, which claims priority to: (1) U.S. Provisional Application No. 61/814,944 filed on Apr. 23, 2013, (2) U.S. Provisional Application No. 61/807,629 filed on Apr. 2, 2013, and (3) U.S. Provisional Application No. 61/735,852 filed on Dec. 11, 2012. The content of each of the above applications is hereby incorporated by reference.This invention was made with government support under Grant no. DMR0805298 awarded by the National Science Foundation. The government has certain rights in the invention.Embodiments of the invention relate generally to the field of medical devices and more particularly to devices that inhibit, reduce, and prevent scarring. Embodiments of the invention include a bioresorbable membrane that can be inserted into the body, between tissues and organs, to prevent unwanted scar tissue attachments.Scar tissue attachments, also called adhesions, are a frequent complication of surgical procedures. During a surgical procedure the tissues and organs of the body may be deliberately or ...

METAL ORGANIC RESINS WITH ZIRCONIUM NODES

Metal organic resins, composite materials composed of the metal organic resins, and anion exchange columns packed with the composite materials are provided. Also provided are methods of using the composite materials to remove metal anions from a sample, methods of using the metal organic resins as fluorescence sensors for detecting metal anions in a sample, and methods of making the metal organic resins and the composite materials. The metal organic resins are amine-functionalized metal organic frameworks and their associated counter anions. The composite materials are composed of metal organic resin particles coated with organic polymers, such as alginic acid polymers.

HYDROGEL COMPOSITES

Disclosed herein is a hydrogel/fibre composite structure producible by a method comprising: partially impregnating fibres of a water-swellable fibrous material with an aqueous hydrogel precursor solution comprising at least one polymerisable, and optionally crosslinkable, monomer such that at least partial swelling of the impregnated fibres takes place, and polymerising, and optionally crosslinking, the at least one monomer after impregnation of the fibres and at least partial swelling of the fibres to form the hydrogel within the impregnated fibres of the fibrous material, such that the integrity of the fibrous material is at least partially preserved in the resulting hydrogel/fibre composite. A method of producing the hydrogel/fibre composite structure and a biomedical product comprising the hydrogel/fibre composite structure are also disclosed herein. 1. A hydrogel/fibre composite structure producible by a method comprising: partially impregnating fibres of a water-swellable fibrous material with an aqueous hydrogel precursor solution comprising at least one polymerisable , and optionally crosslinkable , monomer such that at least partial swelling of the impregnated fibres takes place , and polymerising , and optionally crosslinking , the at least one monomer after impregnation of the fibres and at least partial swelling of the fibres to form the hydrogel within the impregnated fibres of the fibrous material , such that the integrity of the fibrous material is at least partially preserved in the resulting hydrogel/fibre composite.2. A hydrogel/fibre composite structure according to claim 1 , wherein ratio of WA to WW is from 3:1 to 15:1 claim 1 , wherein WA is the weight of fluid (in grams) absorbed in 30 minutes per 100 cmunit area of the hydrogel/fibre composite structure and WW is the weight (in grams) of fluid absorbed in 30 minutes per per unit weight (in grams) of hydrogel/fibre composite structure.3. A hydrogel/fibre composite structure according to claim ...

ALGINATE GUM

The present invention relates to an alginate gum, a method for formation of an alginate gum, optionally in particulate form, and methods of use and the use thereof for example in cheese production. 1. Alginate gum particle or particles , which particle or particles—in uncoated form—have a dry solids content between 80% and 100% w/w; and which particle or particles—in uncoated form—comprise between 0.4% and 1.6% w/w calcium ions on a dry solids basis.2. Alginate gum particles according to claim 1 , comprising at least 50% w/w alginate.3. Alginate gum particle or particles according to claim 1 , having a particle size of between 20 microns and 200 microns in uncoated form.4. Alginate gum particle or particles according to claim 1 , additionally comprising a coating material.5. Alginate gum particle or particles according to claim 1 , being substantially insoluble in milk.6. Alginate gum particle of particles according to claim 1 , comprising a dry solids content between 80% and 100% w/w of sodium alginate claim 1 , and between 0.4% and 1.6% w/w calcium ions on a dry solids basis.7. A method for formation of alginate gum in dry form claim 1 , said method comprising the steps of:a. mixing alginic acid with a calcium salt to obtain a mixture;b. adjusting the pH of the obtained mixture to a pH of between 5.0 and 8.0; andc. drying the mixture to provide alginate gum in dry form.8. The method according to claim 7 , wherein the calcium salt is calcium chloride.9. The method according to claim 7 , wherein the content of calcium ions after mixing with a calcium salt in step a) are between 0.4% and 1.6% w/w calcium ions on a dry solids basis.10. The method according to claim 7 , wherein the adjustment of pH in step b) is to a pH of between 5.0 and 8.0.11. The method according to claim 7 , wherein the adjustment of the pH takes place by addition of a metal carbonate salt such as sodium carbonate.12. The method according to claim 7 , wherein the drying in step c) is to a dry ...

Packaging Films

Films and packaging materials including biodegradable and edible components and pods created using these materials are described herein. 1. A composition comprising a biodegradable polymer and polyhydric alcohol , polyhydric acid , or combinations thereof.2. The composition of claim 1 , wherein the ratio of biodegradable polymer to polyhydric alcohol claim 1 , polyhydric acid claim 1 , or combinations thereof is about 0.5:1 to about 1:10.3. The composition of claim 1 , comprising about 20 wt. % to about 50 wt. % biodegradable polymer.4. The composition of claim 1 , wherein the biodegradable polymer is selected from the group consisting of polylactic acid (polylactide) claim 1 , chitin claim 1 , chitosan claim 1 , alginic acid claim 1 , alginate salts claim 1 , such as claim 1 , sodium alginate claim 1 , calcium alginate claim 1 , magnesium alginate claim 1 , triethanolamine alginate claim 1 , potassium alginate claim 1 , strontium alginate claim 1 , barium alginate claim 1 , or ammonium alginate claim 1 , propylene glycol alginate claim 1 , lignin claim 1 , thermoplastic starch claim 1 , polyethylene claim 1 , polypropylene claim 1 , polyethylene glycol claim 1 , polyglycolide claim 1 , poly (lactide-co-glycolide) claim 1 , polyacrylate claim 1 , polymethacrylate claim 1 , poly (8-caprolactone) claim 1 , polyorthoester claim 1 , polyanhydride claim 1 , polylysine claim 1 , polyethyleneimine claim 1 , carboxymethylcellulose claim 1 , acetylated carboxymethylcellulose claim 1 , gelatin claim 1 , collagen claim 1 , pullulan claim 1 , cold-soluble gelatin claim 1 , pectin claim 1 , locust gum derivatives claim 1 , hydrocolloids claim 1 , kappa carrageenan claim 1 , lambda carrageenan claim 1 , iota carrageenan claim 1 , and derivatives claim 1 , combinations claim 1 , and copolymers thereof.5. The composition of claim 1 , wherein the biodegradable polymer is selected from the group consisting of alginate or alginate salt or combinations of alginate and alginate salts.6. ...

PREPARATION AND/OR FORMULATION OF PROTEINS CROSS-LINKED WITH POLYSACCHARIDES

Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein. 1. A kit comprising:(a) a prefilled syringe, wherein the prefilled syringe is filled with a tissue compatible composition comprising a protein selected from the group consisting of tropoelastin and albumin; a hyaluronic acid cross-linking molecule comprising one or more carboxyl groups; and at least one intermolecular cross-linkage comprising an amide bond between an amine of the protein and a carboxyl group of the hyaluronic acid cross-linking molecule; and(b) instructions for use.2. The kit of claim 1 , further comprising an assortment of appropriate sized needles.3. The kit of claim 2 , wherein the assortment of appropriately sized needles comprise fine gauge needles.4. The kit of claim 3 , wherein the needles range from about 25 gauge to about 31 gauge.5. The kit of claim 2 , wherein the needles range from about 18 gauge to about 31 gauge.6. The kit of claim 1 , further comprising a needle delivery system.7. The kit of claim 6 , wherein the needle delivery system is selected from a needle roller ball type system claim 6 , an automatic injection pen ...

DELAYED ONSET CALCIUM ALGINATE GELS AND METHOD OF PRODUCTION

A method of producing a gel comprises combining an acidic aqueous alginate solution with a second, less acidic aqueous suspension of a calcium salt. A product comprises an alginate-based air treatment gel that is not subject to temperature-induced liquefaction. 1. A method of producing a gel , comprising combining an acidic aqueous alginate solution with a second , less acidic aqueous suspension of a calcium salt.2. The method of wherein the acidic aqueous alginate solution has a pH between 4 and 5.3. The method of claim 1 , wherein the suspension of calcium salt has a pH between 5 and 8.4. The method of claim 1 , wherein the combined solution and suspension has a pH between 4 and 6 immediately after mixing.5. The method of claim 1 , wherein the calcium salt is at least 10 times more soluble at the pH immediately after mixing than in the aqueous suspension.6. The method of claim 1 , wherein the acidic aqueous alginate solution comprises an acidic pH modifier claim 1 , preferably selected from the group consisting of acetic acid claim 1 , citric acid claim 1 , phosphoric acid claim 1 , hydrochloric acid claim 1 , sulfuric acid claim 1 , and lactic acid claim 1 , malic acid claim 1 , and combinations thereof.7. The method of claim 1 , wherein the calcium salt suspension further comprises a suspending agent claim 1 , preferably selected from the group consisting of acacia gums claim 1 , agar claim 1 , acrylic acid claim 1 , albumins claim 1 , carrageenans claim 1 , carbopols claim 1 , casein claim 1 , cellulose gums claim 1 , chitosan claim 1 , chondroitin claim 1 , curdlan claim 1 , gelatin claim 1 , dextran claim 1 , fibrin claim 1 , fulcelleran claim 1 , gellan gum claim 1 , ghatti gum claim 1 , guar gum claim 1 , gum tragacanth claim 1 , heparin claim 1 , hyaluronic acid claim 1 , karaya gum claim 1 , locust bean gum claim 1 , pea protein claim 1 , pectin claim 1 , polyoxyethylene-polyoxypropylene and other synthetic block copolymers claim 1 , pullulan claim 1 , ...

BIODEGRADABLE HYDROPHOBIC COMPOSITE MATERIALS AND PROCESS FOR THE PREPARATION THEREOF

The present invention relates to biodegradable hydrophobic composite materials and a process for the preparation of said hydrophobic biodegradable materials from the seaweed polysaccharides through grafting reaction with vinylated monomers e.g. vinyl acetate. The said composites can be used as a substitute for synthetic ropes for varied applications including seaweed cultivation in the open sea. The results of cultivation experiments showed that ropes are suitable for cultivation of seaweeds in the sea environment, and exhibit higher biomass yield as compared to synthetic ropes. The prepared composites are very flexible and can be used for making handles for carry bags and for the preparation of biodegradable designs, bowls, pots, jars, gift items, stud caps and bracelets. 1. Hydrophobic biodegradable composites comprising:[a] seaweed derived polysaccharides in the range of 30 to 80 wt %;[b] vinylated monomer in the range of 8 to 60 wt %; and[c] plasticizer in the range of 2 to 15 wt %;wherein, the moisture content of said composites is in the range of 5 to 15 wt %.2. The composites as claimed in claim 1 , wherein the seaweed derived polysaccharides are selected from the group consisting of agar claim 1 , agarose claim 1 , alginate claim 1 , and carrageenan.3. The composites as claimed in claim 1 , wherein the seaweed derived polysaccharides are either used alone or in combination.4. The composites as claimed in claim 1 , wherein the seaweed derived polysaccharide is agar and/or agarose.5. The composites as claimed in claim 1 , wherein the vinylated monomer is vinyl acetate.6. The composites as claimed in claim 1 , wherein the plasticizer is selected from the group consisting of glycerol claim 1 , ethylene glycol claim 1 , and sorbitol.7. The composites as claimed in claim 1 , wherein the plasticizer is glycerol.8. A process for the preparation of the composites as claimed in claim 1 , the process comprising:[a] dissolving 1 to 8 wt % of seaweed polysaccharides or ...

Formulations and Kits for Forming Bioadhesive Matrices

A bioadhesive formulation, comprising gelatin, alginate and a coupling agent, capable of forming a bioadhesive matrix, which is characterized by rapid curing, optimal viscosity, high bonding strength, flexibility, biocompatibility and biodegradability, is disclosed. Further disclosed is such a bioadhesive formulation which further comprises a bioactive agent, and a drug-eluting bioadhesive matrix formed therefrom, the bioadhesive matrix being capable of delivering the bioactive agent to a bodily site. Methods utilizing the bioadhesive formulations and matrices in various biological and medical procedures are also disclosed. 1. A kit for preparing a bioadhesive formulation , comprising sub-formulation A and sub-formulation B , said sub-formulation A comprises gelatin and alginate dissolved in water and said sub-formulation B comprises a carbodiimide , whereas combining said sub-formulation A with said sub-formulation B affords the bioadhesive formulation , the bioadhesive formulation being for forming a bioadhesive matrix upon allowing a curing time to elapse , and wherein upon said combining:a concentration of said gelatin in the bioadhesive formulation ranges from 50 mg/ml to 400 mg/ml,a concentration of said alginate in the bioadhesive formulation ranges from 10 mg/ml to 60 mg/ml, anda concentration of said carbodiimide in the bioadhesive formulation ranges from 5 mg/ml to 50 mg/ml,such that prior to curing, the bioadhesive formulation is characterized by a room temperature viscosity that ranges from 1 Pa-sec to 50 Pa-sec, and such that said curing time ranges from 5 seconds to 30 minutes.2. The kit of claim 1 , wherein said carbodiimide in said sub-formulation B is dissolved in water.3. The kit of claim 1 , wherein said matrix is characterized by at least one of:a bonding strength of viable biological objects that ranges from 2,000 pascal to 60,000 pascal;a flexural strength at physiological conditions that ranges from 0.5 MPa to 200 MPa; anda biodegradability ...

COMPOSITIONS AND METHODS FOR MACROPHAGE CONVERSION

One aspect of the invention provides a method of treating a chronic wound including administering to the wound at least one agent from a delivery system wherein the agent induces sequential conversion of a first population of wound macrophages in the wound to M2A macrophages and a second population of wound macrophages to M2C macrophages. The sequential conversion of the wound macrophages promotes tissue remodeling. 1. A method of treating a chronic wound comprising administering to the wound at least one agent from a delivery system wherein the agent induces sequential conversion of a first population of wound macrophages in the wound to M2A macrophages and a second population of wound macrophages to M2C macrophages , wherein the sequential conversion of the wound macrophages promotes tissue remodeling.2. The method of claim 1 , wherein the delivery system is a composition selected from the group consisting of: a hydrocolloid composition claim 1 , a hydrogel claim 1 , a polysaccharide-based composition claim 1 , a semi-permeable polymeric adhesive film composition claim 1 , a foam composition claim 1 , a biological composition claim 1 , a polymeric scaffold claim 1 , a sequential controlled-release delivery system claim 1 , and a layer-by-layer delivery system.3. The method of claim 1 , wherein the delivery system comprises IL-4 bound to the delivery system through a binding molecule.4. The method of claim 3 , wherein the binding molecule is non-covalently bound to the delivery system.5. The method of claim 3 , wherein the IL-4 is covalently bound to an affinity molecule that interacts with the binding molecule.6. The method of claim 3 , wherein the IL-4 is released by dissociating the IL-4 from the binding molecule.7. The method of claim 3 , wherein the delivery system further comprises IL-10 bound to the delivery system through a binding molecule.8. The method of claim 7 , wherein the IL-10 is bound to an affinity molecule that interacts with the binding molecule ...

Alginate gum

The present invention relates to an alginate gum, a method for formation of an alginate gum, optionally in particulate form, and methods of use and the use thereof for example in cheese production.

Polymers, Thermochromic Agents, And/Or Hydrogel Compositions And Apparatus, Including Products Embodying The Same, And Methods And Processes For Making Same

Polymers, hydrogels, and thermochromic agents, including products embodying them, methods of using them, and processes for making them. In certain embodiments, temperature therapy packs which utilize thermochromic agents integrated into solid, semi-solid, or liquid hydrogels. In preferred (but optional) embodiments, the thermochromic agents are integrated into the composition used as the temperature exchange material of the therapy pack. In certain other embodiments, methods of using the thermochromic integrated temperature exchange materials, or processes for manufacturing such thermochromic integrated temperature exchange materials and/or methods or processes for manufacturing or using thermal packs embodying such materials. In certain particularly preferred embodiments, novel polymer compositions and/or processes for making polymers, which improve product durability or longevity and/or which improve use cycles or usage times.

Agent for Treating Urinary Incontinence Including Stem Cells Derived from Amniotic Fluid

The present invention relates to a cell therapy product which is intended for regenerating a sphincter muscle and which contains stem cells derived from amniotic fluid, and more particularly, to a cell therapy product which is intended for regenerating the sphincter vesicae and which contains stem cells derived from amniotic fluid. Also, the cell therapy product of the present invention can be provided in the form of a formulation for administration through injection, said formulation being injected into a hydrogel complex to thereby improve the effects thereof. The composition including stem cells derived from amniotic fluid according to the present invention enables stem cells to be differentiated into muscles in the body of individual suffering from urinary incontinence by directly injecting the composition into the individual, thus effectively controlling urinary incontinence by recovering muscle functions. That is, the stem cells derived from amniotic fluid of the present invention are differentiated into muscles in-situ, and the differentiation into muscles can thus be achieved only with cells in order to recover muscle functions. 111-. (canceled)12. A method for treating a subject for urinary incontinence , the method comprising:administering directly to a sphincter deficiency area of the subject an effective amount of a hydrogel composition comprising an alginate/pluronic acid F-127 (Pluronic F-127, PF-127)/hyaluronic acid complex, into which amniotic fluid-derived stem cells are impregnated, wherein the alginate, Pluronic F-127 and hyaluronic acid are present in the hydrogel in a volume ratio of 6:6:1, respectively, such that the amniotic fluid-derived stem cells differentiate in situ into myocytes in vivo.13. The method according to claim 12 , wherein the hydrogel composition is formulated in the form of an injection formulation.14. The method according to claim 12 , wherein the administering comprises directly injecting the composition into the sphincter ...

Hydrogels Based On Functionalized Polysaccharides

The present invention relates to functionalized hydrogel networks grafted with at least one moiety for use in numerous fields, from cosmetics to surgery and medicine.

Novel manufacturing and applications of adhesive materials

A novel method of manufacturing and applications of a composition of matter comprising of a cross-linked form of a polysaccharide, at least one cross-linking agent comprised of divalent ions for effecting said cross-linked form of said polysaccharide, and at least one synthetically prepared phloroglucinol compound selected from the group comprising of phloroglucinol, a derivative of phloroglucinol, and a polymer synthetically prepared from phloroglucinol or a derivative of phloroglucinol, as an adhesive in procedures for reattaching or repairing body parts or components thereof, such as tissue, of (human or animal) subjects, especially under wet conditions, for example, involving adhesion of wet surfaces.

Iron complexing agent and uses thereof in the treatment and prevention of colorectal cancer

A complex comprising a non-absorbable portion attached to an iron chelator moiety, a composition comprising the complex and the use of the complex in the treatment of colorectal cancer. In one embodiment the non-absorbable portion is a polymer such as a polysaccharide, including chitosan, chitin, cellulose or pectin. In one embodiment the iron chelator moiety comprises at least one functional group selected from catechol, hydroxamate or carboxylate, or any combination thereof.

Porous nanocomposite polymer hydrogels for water treatment

Synthesis, fabrication, and application of nanocomposite polymers in different form (as membrane/filter coatings, as beads, or as porous sponges) for the removal of microorganisms, heavy metals, organic, and inorganic chemicals from different contaminated water sources.

Emulsion coagulant

An object of the present invention is to provide an emulsion coagulant which can be used to quickly coagulate a tire puncture sealing material in an extremely low temperature environment. The emulsion coagulant of the present invention is an emulsion coagulant comprising: component (A) having a particle size of from 35 to 100 μm and comprising at least one type selected from the group consisting of aluminum oxide, magnesium oxide, and silicon oxide; propylene glycol alginate; and component (B) comprising at least one type selected from the group consisting of calcium oxide, calcium chloride, calcium acetate, and urea; the amount of component (B) being from 3 to 30 mass % of the total amount of component (A), propylene glycol alginate, and component (B); and the emulsion coagulant being used to coagulate a tire puncture sealing material comprising an emulsion.

Improved biorefinery of brown macroalgae

The present invention concerns an improved process for biorefinery of brown macroalgae, which comprises: (a) contacting the brown macroalgae with a solvent system comprising at least 30 wt % organic solvent, to obtain extracted macroalgae as solid residue and a liquor; and (b) biorefining the extracted macroalgae. The inventors have found that the contacting of step (a) results in an efficient and cost-effective dewatering of the macroalgae, wherein up to 95 wt % of the internal moisture of the macroalgae could be lost without the need for energy-consuming drying techniques. As such, the downstream biorefinery of the extracted macroalgae is greatly facilitated.

Polymers, thermochromic agents, and/or hydrogel compositions and apparatus, including products embodying the same, and methods and processes for making same

Polymers, hydrogels, and thermochromic agents, including products embodying them, methods of using them, and processes for making them. In certain embodiments, temperature therapy packs which utilize thermochromic agents integrated into solid, semi-solid, or liquid hydrogels. In preferred (but optional) embodiments, the thermochromic agents are integrated into the composition used as the temperature exchange material of the therapy pack. In certain other embodiments, methods of using the thermochromic integrated temperature exchange materials, or processes for manufacturing such thermochromic integrated temperature exchange materials and/or methods or processes for manufacturing or using thermal packs embodying such materials. In certain particularly preferred embodiments, novel polymer compositions and/or processes for making polymers, which improve product durability or longevity and/or which improve use cycles or usage times.

STAPLED ACID-SENSITIVE ENDOSOME DISRUPTING ALGINATES

An agent comprising: 1. An agent comprising:an algin monosaccharide residue covalently bonded to an acetal group forming an alginoketal; andat least one cation coupled to the alginoketal.2. The agent of claim 1 , wherein the cation is selected from copper claim 1 , iron claim 1 , calcium claim 1 , zinc claim 1 , magnesium claim 1 , selenium claim 1 , aluminum claim 1 , manganese claim 1 , barium claim 1 , strontium or a combination thereof.3. The agent of claim 1 , wherein the cation is chelated to the alginoketal.4. The agent of claim 1 , wherein the agent includes at least two different types of cations.5. The agent of claim 1 , wherein the cation is calcium6. A method for treating a neoplasm or neurodegenerative disorder in a subject claim 1 , comprising administering to a subject in need thereof a therapeutically effective amount of an agent comprising an algin crosslinked with acetal linkages; and at least one cation coupled to the crosslinked algin.8. The method of claim 7 , wherein the neoplasm is cancer.9. The method of claim 8 , wherein the cancer is fibrosarcoma claim 8 , myxosarcoma claim 8 , liposarcoma claim 8 , chondrosarcoma claim 8 , osteogenic sarcoma claim 8 , chordoma claim 8 , angiosarcoma claim 8 , endotheliosarcoma claim 8 , lymphangiosarcoma claim 8 , lymphangioendotheliosarcoma claim 8 , synovioma claim 8 , mesothelioma claim 8 , Ewing's tumor claim 8 , leiomyosarcoma claim 8 , rhabdomyosarcoma claim 8 , colon carcinoma claim 8 , pancreatic cancer claim 8 , breast cancer claim 8 , ovarian cancer claim 8 , prostate cancer claim 8 , squamous cell carcinoma claim 8 , basal cell carcinoma claim 8 , adenocarcinoma claim 8 , sweat gland carcinoma claim 8 , sebaceous gland carcinoma claim 8 , papillary carcinoma claim 8 , papillary adenocarcinomas claim 8 , cystadenocarcinoma claim 8 , medullary carcinoma claim 8 , bronchogenic carcinoma claim 8 , renal cell carcinoma claim 8 , hepatoma claim 8 , bile duct carcinoma claim 8 , choriocarcinoma claim 8 ...

SYSTEM AND METHOD FOR INTRAOPERATIVE JOINT CONTACT MECHANICS MEASUREMENT

A method for intraoperatively measuring joint contact mechanics of a patient's joint is provided. The method includes inserting a sensor between first and second bones of a joint. Then a predetermined force is applied to one of the first and second bones. Afterwards, contact mechanics such as, contact stresses, contact areas and/or forces are measured between the first and second bones in response to the applied predetermined force. 1. An instrumented surgical mount comprising:a fastener for attaching to a patient;a force plate mounted to the fastener;a load cell mounted to the force plate for measuring applied loads; anda handle assembly attachable to the load cell.2. The instrumented surgical mount of claim 1 , further comprising a computer operatively in communication with the load cell for recording measured applied loads.3. The instrumented surgical mount of claim 1 , wherein the load cell is a uniaxial or multi-axis load cell.4. The instrumented surgical mount of claim 1 , further comprising a mechanized device to apply a controlled force to the load cell or apply a controlled displacement to the load cell.5. The instrumented surgical mount of claim 1 , wherein the load cell is detachable from the handle assembly.6. The instrumented surgical mount of claim 1 , wherein the fastener is a surgical shoe for engaging a foot of the patient.7. The instrumented surgical mount of claim 1 , further comprising a goniometer for recording translations and/or rotations resulting from applied loads to the load cell.8. The instrumented surgical mount of claim 1 , further comprising a surgical navigation system for tracking the patient and at least one of the fastener claim 1 , force plate claim 1 , load cell and handle assembly.9. The instrumented surgical mount of claim 1 , further comprising a mounting assembly for housing the load cell claim 1 , the mounting assembly comprising:a first spacer having a through hole for receiving the load cell;a second spacer having a ...

COMPOSITE MATERIALS CONTAINING ORGANIC POLYMER-ENCAPSULATED METAL ORGANIC FRAMEWORKS

Metal organic resins, composite materials composed of the metal organic resins, and anion exchange columns packed with the composite materials are provided. Also provided are methods of using the composite materials to remove metal anions from a sample, methods of using the metal organic resins as fluorescence sensors for detecting metal anions in a sample, and methods of making the metal organic resins and the composite materials. The metal organic resins are amine-functionalized metal organic frameworks and their associated counter anions. The composite materials are composed of metal organic resin particles coated with organic polymers, such as alginic acid polymers. 1. A composite material comprising:metal organic resin particles comprising metal organic frameworks and associated counter anions, wherein the metal organic frameworks comprise metal nodes coordinated via organic molecular linkers to form a connected porous network and further wherein the organic molecular linkers are protonated and amine-functionalized; andan organic polymer coating the metal organic resin particles.2. The composite material of claim 1 , wherein the organic polymer is an alginic acid polymer.3. The composite material of claim 1 , wherein the counter anions are halide anions.4. The composite material of claim 3 , wherein the halide anions are chloride ions.5. The composite material of claim 1 , wherein the metal nodes of the metal organic frameworks are Zrnodes.6. The composite material of claim 5 , wherein the metal organic resins have the formula: [ZrO(OH)(HO)(HPATP)]X claim 5 , or the same formula claim 5 , but with oxo ligands claim 5 , aquo ligands claim 5 , or a combination thereof in place of some or all of the hydroxo ligands claim 5 , where HPATP is 2-((pyridine-1-ium-2-ylmethyl)ammonio)terephthalate and X is a monovalent anion.7. The composite material of claim 6 , wherein the organic polymer is an alginic acid polymer.8. The composite material of claim 5 , wherein the ...

Deposition-Conversion Method For Tunable Calcium Phosphate Coatings On Substrates And Apparatus Prepared Thereof

The present invention relates to a method for in situ biomimetic mineralization of polymeric hydrogels, where the incorporated CaP phase can be selectively tuned in chemical composition and morphology to mimic bone and dental mineral. The present invention also relates to a method to coat a substrate with apatite material, the resulting product and the use of the product.